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Skeletal pathology is common in patients with end-stage liver disease before and after 
orthotopic liver transplantation (OLT), and this is associated with significant morbidity 
and decreased quality of life. Significant bone loss occurs and the incidence of new 
fractures is high within the first year after OLT, despite recovery of liver function. (1-4) 
However, the pathophysiology of increased bone fragility in end-stage liver disease 
and after liver transplantation remains incompletely understood. A number of risk 
factors, such as vitamin D deficiency, hypogonadism, malnutrition, alcohol abuse and 
glucocorticoid use where applicable contribute to bone loss and increased fracture risk, 
but the persistence of increased fracture risk after correction of metabolic abnormalities 
after liver transplantation suggests that other factors, as yet to be identified, are likely 
to be involved in the pathophysiology of skeletal complications after OLT.
The aim of this Chapter is to provide an overview on the role of the liver in bone 
metabolism and on the pathophysiology of bone loss and increased fracture risk 
observed in liver diseases before and after liver transplantation.
normal bone remodeling
The skeleton is constantly renewed by the process of bone remodeling which plays a major 
role in the preservation of calcium and phosphate homeostasis, and in the maintenance 
of the structural integrity of bone by preserving bone mass. Bone remodeling takes place 
in the so called bone multicellular units (BMU’s) through the coordinated activity of the 
3 types of bone cells: osteoblasts, osteoclasts and osteocytes. The remodeling cycle starts 
with the resorption of bone by osteoclasts, followed by the formation of new bone by 
osteoblasts, which fills the resorption cavities created by the osteoclasts. Mineralization of 
the newly formed osteoid completes the bone remodeling cycle. (Figure 1)
Bone remodeling is regulated by several factors including hormones, signaling 
pathways and mechanical factors. Two signaling pathways are crucial for the 
differentiation, maturation, activation and survival of bone cells, the RANK/RANKL/OPG 
pathway for osteoclasts and the Wnt signaling pathway for osteoblasts. Differentiation 
of osteoclasts from hematopoietic stem cells is mediated through the RANK/RANKL/
OPG pathway (5;6) in the presence of the macrophage-colony stimulating factor 
(M-CSF), which induces RANK expression in osteoclast progenitor cells. Binding of 
the ligand of RANK (RANKL), produced by the osteoblast, to its receptor RANK on the 
surface of pre-osteoblasts induces a cascade of signaling pathways, which affects all 
steps of osteoclastogenesis. All these steps are in turn inhibited by osteoprogerin (OPG), 
a natural decoy receptor also produced by the osteoblast, which binds to RANKL, and 
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preventing its binding to RANK, and thus inhibiting all steps of osteoclastogenesis when 
this is no longer required.(Figure 2)
The Wnt signaling pathway is a critical regulator of bone formation (6;7), which when 
activated, results in binding between Wnt proteins (Figure 3), Frizzled and low density 
lipoprotein receptor-related protein 5 (LPR-5) or LPR-6 receptors. This results in inactivation 
of GSK-3beta, inhibition of beta-catenin degradation and accumulation of beta-catenin 
in the nucleus.(8) Beta-catenin binds to the TCF/LEF family of transcription factors and 
induces target gene expression, which is essential for the differentiation of mesenchymal 
stem cells to osteoblasts through effects on proliferation and maturation of osteoblast 
progenitor cells. The transcriptional factor RUNX2 is a target of beta-catenin for the 
stimulation of bone formation through the initiation of differentiation of multipotent 
mesenchymal stem cells into osteoblasts.(9) Osterix, another transcription factor, acts 
downstream of RUNX2 and is responsible for the transition from osteoprogenitor cells to 
pre-osteoblasts. Later in the process of osteoblast differentiation, beta-catenin influences 
bone resorption by decreasing osteoclastogenesis through stimulation of the expression 
of OPG.(10) The Wnt singalling pathway is antagonized by sclerostin, a protein produced 
by osteocytes, which is a product of the Sost-gene and binds to LPR-5 and LPR-6, thereby 
preventing the formation of the complex between Wnt proteins and Frizzled.(11) In 
addition to sclerostin, members of the Dickkopf (DKK) family such as DKK-1 also inhibit 
the Wnt signalling pathway by binding to the LPR-5 and LPR-6 receptors.(12) Secretion of 
sclerostin by the osteocyte is suppressed by mechanical stress, leading to increased bone 
formation.(6)
Figure 1: The bone remodeling cycle, which starts with the resorption of bone by osteoclasts, followed 
by the formation of new bone by osteoblasts, which fills the resorption cavities created by the osteo-
clasts. Mineralization of the newly formed osteoid completes the bone remodeling cycle. Osteoclasts 
that are trapped in the matrix become osteocytes; others die or form new, flattened osteoblast lining 
cells. (Reproduced with permission from Seeman E, Delmas PD N Engl J Med 2006; 354(21):2250-2261, 




Figure 2: The RANK/RANKL/OPG patway. Binding of the ligand of RANK (RANKL), produced by the osteo-
blast, to its receptor RANK on the surface of pre-osteoblasts induces a cascade of signaling pathways, 
which affects all steps of osteoclastogenesis (upper panel, a). All these steps are in turn inhibited by 
OPG, a natural decoy receptor also produced by the osteoblast, which binds to RANKL, and preventing 
its binding to RANK, and thus inhibiting all steps of osteoclastogenesis when this is no longer required 
(lower panel, b). OPG = osteoprogerin; RANK = receptor activator of nuclear factor kappa b; RANKL = 
receptor activator of nuclear factor kappa B- ligand; PTH = parathyroid hormone; PTHrP = parathy-
roid hormone related peptide; PGE-2 = prostaglandin E2; IL = interleukin; TNF = tumor necrosis factor; 
BMP = bone morphogenic protein; TGF-beta = transforming growth factor beta; TPO= thrombopoietin; 
PDGF = platelet derived growth factor (Adapted from Boyle WJ, Simonet WS, Lacey DL. Nature 2003; 
423(6937):337-342, reproduced with permission)
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The tightly regulated process of bone remodeling is thus controlled by a number of 
regulatory signals, which have been largely although as yet somewhat incompletely 
unraveled.(6) Metabolic bone activity can be evaluated in the clinic by measuring 
circulating products of bone remodeling activity. Biochemical markers of bone 
Figure 3: The Wnt signaling pathway. Activation of Wnt signaling results in binding between Wnt pro-
teins, FZD and LPR5 or LPR6 receptors (right panel). This results in inactivation of GSK-3beta, inhibi-
tion of beta-catenin degradation and accumulation of beta-catenin in the nucleus. Beta-catenin binds 
to the TCF/LEF family of transcription factors and induces target gene expression, which is essential 
for the differentiation of mesenchymal stem cells to osteoblasts through effects on proliferation and 
maturation of osteoblast progenitor cells. The Wnt singalling pathway is antagonized by sclerostin, 
a protein produced by osteocytes, which is a product of the Sost-gene and binds to LPR-5 and LPR-6, 
thereby preventing the formation of the complex between Wnt proteins and FZD (left panel). In ad-
dition to sclerostin, members of the DKK family also inhibit the Wnt signalling pathway by binding to 
the LPR-5 and LPR-6 receptors. SFRP= secreted frizzled-related proteins; LRP= low density lipoprotein 
receptor-related protein; FZD =Frizzled; APC= adenomatous polyposis; P= phosphorylation; Ub = polyu-
biquitination; DVL = dishevelled; TCF/LEF = T cell factor/lymphoid enhancer factor; PTH= parathyroid 
hormone; DKK1 =Dickkopf-1; WIF1= Wnt inhibitory factor 1; DAAM1= dishevelled associated activator of 
morphogenesis 1; IP3 = inositol 1,4,5-trisphosphate, type 3; JNK = Jun kinase; ROCK = RHO-associated ki-
nase; PPAR-gamma = peroxisome proliferator activated receptor-γ. NFATc1 = nuclear factor of activated 
T cells, cytoplasmic, calcineurin dependent 1; ROR = receptor-tyrosine-kinase-like orphan receptor; PLC 
= phospholipase C; DAG = dystroglycan: RUNX2 = Runt-related transcription factor 2. (Adapted from 
Baron R, Kneissel M. Nat Med 2013; 19(2):179-192, reproduced with permission) 
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1remodeling activity, the bone turnover markers, include circulating crosslink fragments of degraded collagen: serum beta-crosslaps (CTX), as well as the urinary excreted 
crosslink fragments: hydroxyproline, pyridinoline, deoxypyridinoline and type 1 collagen 
cross-links (NTX and CTX). The products of various stages of bone formation, procollagen 
type 1 N-terminal propeptide (P1NP), osteocalcin and bone alkaline phosphatase 
(BALP), each representing a different stage of maturation of the osteoblast, can also be 
measured in serum. The gold standard of evaluation of metabolic bone disease remains 
the double tetracycline labeled bone biopsy, which provides information on bone cell 
activity as well as mineralization.
role of the liver in normal bone remodeling
The two main physiological functions of the liver are metabolic and excretory, and 
various aspects of both functions play an important role in normal bone remodeling and 
thus in the maintenance of skeletal health.
metabolic functions of the liver of relevance for skeletal health
Vitamin D metabolism
The liver plays an important role in skeletal and calcium homeostasis through its 
role in vitamin D metabolism. Vitamin D, a fat soluble vitamin, is synthesized in the 
skin by the effect of UV radiation from sun light on 7-dehydrocholesterol. Intestinal 
absorption of dietary vitamin D is a much less important source of vitamin D as this is 
mainly found in fatty fish and essentially scarce in a normal diet. Dietary vitamin D is 
absorbed by enterocytes, incorporated into micelles, packaged into chylomicrons and 
transported to the liver via the portal circulation. Vitamin D is metabolically converted 
in the liver to the pro-vitamin D hormone, 25-hydroxy vitamin (25(OH)D), by cytochrome 
p450 enzymes, which exhibit a high capacity for the substrate vitamin D3. 25(OH)D is 
converted to the biologically active ligand for the widely distributed vitamin D receptor 
(VDR) through activity of the renal one-alpha hydroxylase (CMP27B1) enzyme. The 
proximal renal tubular epithelial cell is the largest source of the 1-alpha hydroxylase 
enzyme but the enzyme has also been found to be present in a large number of cells 
resulting in the extra-renal intracellular production of biologically active 1,25(OHD)2D 
(calcitriol), which is primarily governed by the availability of extracellular 25(OH)
D as substrate. The VDR is expressed in virtually all nucleated cells and influences 
a wide variety of processes such as proliferation, differentiation, apoptosis, mineral 
homeostasis, immune response and metabolism.(6;13) The vitamin D-binding protein 
(DBP), a member of the albumin family of proteins, is mainly produced by the liver and 
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is essential for binding of vitamin D and its metabolites in serum and for delivery of 
its biologically active form 1,25(OH)2D to target tissues expressing the VDR. The most 
important biological action of vitamin D in the control of calcium homeostasis is the 
promotion of enterocyte differentiation, the intestinal absorption of calcium and the 
suppression of parathyroid hormone (PTH) synthesis and release by the parathyroid 
gland. In bone, the VDR regulates osteoblast and osteoclast function and is also 
important for bone mineralization.(6;14;15) VDR controls bone remodeling by regulating 
the production of RANKL and OPG by osteoblasts and osteocytes, thus playing a major 
role in the coupling of bone formation and resorption and in the maintenance of bone 
mass and integrity. Bone resorption is decreased by VDR activity by suppression of the 
RUNX2 gene transcription in the Wnt signaling pathway . Activation of the VDR also 
leads to production of osteopontin (OPN) by the osteoblasts, a peptide believed to be 
involved in bone mineralization and remodeling by anchoring osteoblasts to the mineral 
matrix.(6;15) VDR also affects the osteocalcin gene, the function of which in bone is 
incompletely understood, (6;15) although it has been suggested this osteoblast-specific 
protein may contribute to the density and structural integrity of bone.
A feedback loop is formed by the formation of fibroblast growth factor (FGF-23) by 
VDR signaling in the osteocyte.(6;15) FGF-23 inhibits the renal 1-alpha-hydroxylaze 
enzyme and thereby the conversion of calcidiol to the biologically active calcitriol 
(1,25OH)2D), simultaneously inducing the degradation of 1,25(OHD)2D to the biologically 
inactive metabolite 24,25(OH)2D by increasing the expression of the 24-alpha-
hydroxylase enzyme.
Metabolism of gonadal steroids
Gonadal steroids play an important regulatory role on bone and mineral metabolism. 
Sex steroid deficiency results in high bone turnover in favor of increased bone 
resorption, leading to loss of bone mass and bone strength and to an increase in fracture 
risk. The liver is the main site for peripheral inactivation and clearance of estrogens. 
Furthermore, sex-hormone binding globulin (SHBG) and albumin, the most important 
serum binding proteins for testosterone and estradiol, are synthesized in the liver.
Insulin-like growth factor 1
Bone remodeling is influenced by insulin-like growth factor-1 (IGF-1), a growth factor 
synthesized in the liver under the influence of growth hormone (GH).(16-18) To a lesser 
extent, IGF-1 is also produced in bone under the influence of GH as well as of local 
factors, with bone-derived IGF-1 also playing an important role in bone remodeling.(17) 
IGF-1 circulates mostly as a complex of IGF-1 bound to IGF-binding-protein-3 (IGFBP-3), 
one of the IGF-binding-proteins (IGFBP’s).(19) IGFBP-concentrations and IGF-1 expression 
are regulated by various hormones, including GH, testosterone, estrogen and thyroid 
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1hormones.(18) IGF-1 stimulates osteoblast function and bone formation by mitogenic activity and by stabilization of beta-catenin, thereby enhancing Wnt-dependent activity.
(20-22) On the other hand, IGF-1 also induces RANK-L synthesis thereby promoting 
osteoclastogenesis and osteoclast function.(20;23) Furthermore, IGF-1 maintains the 
bone matrix by influencing collagen transcription and collagenase production.(20) 
IGF-1 is also believed to be necessary for the action of PTH on bone; PTH increases IGF-1 
expression in osteoblasts and IGF-1 in turn mediates the anabolic action of PTH on 
the skeleton.(18;20;24;25) Systemic IGF-1 appears to contribute more to cortical bone 
integrity, whereas locally bone-derived IGF-1 is thought to play a more important role in 
the maintenance of trabecular bone integrity (20)
excretory function of the liver
One of the main excretory functions of the liver is the synthesis and excretion of bile 
salts, which contribute significantly to normal calcium and bone homeostasis as they 
are essential for the absorption of the lipid soluble vitamin D.(26) Bile acid synthesis 
starts with the synthesis of the two primary bile acids, cholic acid en chenodeoxycholic 
acid, by the process of oxidation of cholesterol in liver cells. These bile acids are secreted 
into the lumen of the intestine, where intestinal bacteria partly dehydroxylate them to 
the secondary bile acids, deoxycholic acid and lithocholic acid. The secondary bile acids 
are in turn reabsorbed in the ileum and transported to the liver via the portal circulation, 
and are re-secreted, creating an enterohepatic circulation. Bile acids are secreted after 
conjugation with glycine or taurine, forming a total of eight possible conjugated bile 
acids. These are referred to as bile salts. Bile salts are more water-soluble than bile 
acids. They are able to emulsify lipids and fat-soluble vitamins (such as vitamin D) in the 
intestine, to form micelles that can be transported to the liver.(26)
Vitamin K metabolism and bone
Bile salts are necessary for the absorption of vitamin K, a fat-soluble vitamin necessary 
for the production of osteocalcin in bone. Vitamin KI is mainly found in leafy vegetables 
and absorbed in the small intestine, and vitamin KII is synthesized by bacterial flora and 
found in animal liver and fermented foods.(27) Absorption of vitamin K is dependent on 
pancreatic function and on the presence of bile salts and it is excreted as its catabolic 
product in bile and urine. A proportion of vitamin K is stored in the liver.(27)
Osteocalcin is the most abundant non-collagenous protein in bone, which is produced 
by the osteoblasts and incorporated into the bone matrix, where it is involved in bone 
calcification. Vitamin K is essential for the post-translational carboxylation of glutamic 
acid, which is necessary for binding of calcium to the proteins found in bone such as 
osteocalcin. Vitamin K has also been shown to inhibit osteoclast formation by affecting 
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RANK-L production, and to stimulate bone formation by enhancing osteoblastogenesis 
and promoting osteoblast to osteocyte formation.(27;28)
factors affecting bone remodeling in liver disease
In liver disease, the metabolic and excretory functions of the liver are compromised to a 
lesser or greater extent by the underlying pathology, leading to disturbances in calcium 
and bone metabolism. Viral pathogens, toxins such as alcohol or accumulated bile salts, 
and medication potentially used to treat the liver disease such as corticosteroids in 
auto-immune hepatitis may also exert direct deleterious effects on bone independently 
of the disturbed hepatobiliary function.
vitamin d deficiency
Vitamin D deficiency is common in chronic liver disease, with a prevalence ranging 
from 64-92%, which increases with the severity the disease.(29;30) In liver disease, 
the pathogenesis of vitamin D deficiency is multifactorial, including poor nutritional 
status, decreased sun light exposure due to chronic illness and decreased vitamin 
D absorption in cholestatic liver diseases. In the late stages of liver disease, the 
production of the 25 hydroxylase enzyme is also impaired and increased breakdown 
of 25(OH)D to biologically inactive metabolites decreases substrate availability for 
the renal production of the biologically active 1,25(OH)2D. This leads to decreased 
intestinal absorption of calcium, hypocalcemia, and secondary hyperparathyroidism.(31) 
Decreased VDR signaling results in further stimulation of PTH synthesis and increased 
bone turnover in favour of bone resorption. Bone mineralization is also significantly 
compromised by vitamin D deficency, resulting first in a decrease in bone mass and 
eventually in case of longstanding severe vitamin D deficiency to osteomalacia.
In patients with chronic liver disease, vitamin D deficiency is mainly due to decreased 
sunlight exposure and malnutrition.(32) 25-hydroxylation of vitamin D remaining 
generally intact until the late stages of liver failure when more than 90% of liver 
function is lost.(30;33) Cholestasis such as occurs in primary biliary cirrhosis (PBC), 
primary sclerosing cholangitis (PSC) and overlap syndromes with auto-immune hepatitis 
(AIH), negatively influences vitamin D metabolism.(32;34;35) In these diseases, in which 
transportation of bile salts to the intestine is compromised, the resulting decrease in 
bile salts leads to defective absorption of fat-soluble vitamins including dietary vitamin 
D.(32;34;35) In patients with PSC the often concomitant inflammatory bowel disease, 
Crohn’s disease, may in its own right contribute to decreased intestinal re-absorption 
of bile salts and of vitamin D through mucosal inflammation or surgical resection of 
significant length of the small intestine to control disease activity.(35) In addition to 
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1the effect of cholestasis on the intestinal absorption of vitamin D, cholestatic toxins may also directly influence bone remodeling through a direct toxic effect on various 
steps of the RANK/RANKL signaling pathway and on mediators of osteoblast function, 
thereby inhibiting bone formation and increasing bone resorption.(30). A large fraction 
of vitamin D is bound to DBP and albumin so that reduced production of these proteins 
in the liver also leads to a decrease in circulating vitamin D and in its availability for 
metabolic functions, particularly in the late stages of liver failure.(30)
hypogonadism
Gonadal hormone deficiency is common in liver disease. Estrogen and testosterone 
attenuate the maturation of osteoclasts and inhibit bone resorption by the stimulation 
of osteoclast apoptosis while preventing osteoblast and osteocyte apoptosis thus 
maintaining a healthy balance between bone resorption and formation leading to 
preservation of bone mass and integrity. A decrease or loss of sex steroids therefore 
leads to increased osteoclast activity and accelerated bone resorption.
However, the aetiology of hypogonadism in liver failure is not completely understood. 
It may develop as a result of primary gonadal failure as well as a result of failure of the 
pituitary-hypothalamic gonadal axis. Alcohol abuse is associated with central as well 
as primary gonadal hypogonadism, independently of cirrhosis or nutritional status. 
Alcohol also accelerates the metabolic clearance of testosterone, leading to decreased 
circulating testosterone levels.(36) Some studies also suggest that alcohol increases 
hepatic aromatization of androgens to estrogen in men, although this would not be 
deleterious to the skeleton.(37) In hereditary and secondary hemochromatosis, pituitary 
iron deposition leads to destruction of gonadotroph cells with consequent secondary 
hypogonadism.(38-40) In patients with end-stage liver disease, testosterone levels 
decline while SHBG increases, leading to decreased free testosterone levels.(4)
renal impairment
Renal disease is common in patients with liver disease with a reported prevalence of 20-
25% of patients.(41) The later stages of liver failure may be associated with renal failure: 
the hepatorenal syndrome. Renal IgA deposition is often seen in liver disease and may 
result in IgA nephropathy, especially in the case of alcoholic liver disease. Viral hepatitis 
is associated with membranous and membranoproliferative glomerulonephritis and 
focal segmental glomerulosclerosis. In patients with diabetes and steatohepatitis, 
co-existing diabetic nephropathy may also lead to renal impairment.
Renal impairment has complex deleterious effects on bone, on one hand through 
phosphate retention and consequent progressive stimulation of FGF-23 production, 
and on the other hand through chronic stimulation of the parathyroids resulting in 
hyperplasia and proliferation of these cells.(42;43) Secondary hyperparathyroidism 
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results from phosphate retention and from decreased calcium- and calcitriol 
concentrations.(43) Calcitriol concentrations are reduced due to suppressed renal 
1-alpha hydroxylase activity, which result from phosphate retention and increased FGF-
23 concentrations.(43;44) In severely impaired renal function, loss of functional renal 
mass leads to decreased 1-alpha hydroxylase production, also contributing to the decline 
in calcitriol concentration.(44) Nutritional vitamin D deficiency and loss of 25(OH)D are 
also very common in renal failure, also contributing to secondary hyperparathyroidism. 
High or low bone turnover may both be associated with osteoporosis and increased 
fracture risk in patients with renal failure.(45-48)
igf-1
Liver diseases are associated with low IGF-1 levels, and these have been shown to 
be associated with low bone mass and increased fracture risk in growth hormone 
deficiency states.(49) The contribution of low IGF-1 levels to decreased bone mass in 
patients with liver disease has not however been adequately addressed so far.(50)
A decrease in IGF-1 levels is observed in the early stages of liver disease, such as 
fibrosis and steatosis, and in alcoholics (51-53) and IGF-1 levels progressively decline with 
further deterioration in liver function.(52-57) In liver diseases, the aetiology of decreased 
IGF-1 levels is multifactorial. A decrease in hepatocyte function leads to a decrease 
in hepatic IGF-1 and IGFBP-3 secretion. (50-56;58-63) Interestingly, GH levels have 
been shown to be increased in these patients (50-56;58-63), suggesting hepatic GH-
resistance, which may be related to malnutrition.(59). Low IGF-1 levels are also common 
in inflammatory bowel disease, such as Crohn’s disease which is associated with PSC. 
Moreover, IGF-1 production may be inhibited by inflammatory cytokines such as IL-6, 
which are released during infections such as spontaneous bacterial peritonitis.(64) 
Although hormone deficiencies such as testosterone, insulin and thyroxine deficiencies 
which are prevalent in liver diseases may lead to an increase if IGFPB-3 and therefore to 
an increase in unbound IGF-1, a decrease of IGFBP-3 is actually observed in most patients 
with compromised liver function.
vitamin K
In liver disease, vitamin K deficiency may occur as a result of malnutrition and of 
decreased intestinal absorption of vitamin K in cholestatic disease due to a decrease in 
bile salt excretion in the intestine. Small-intestine pathology such as Crohns’ disease 
may also lead to decreased vitamin K absorption. In case of vitamin K insufficiency, 
osteocalcin fails to become carboxylated in bone, and it is released from the osteoblasts 
into the circulation.(65) Low circulation levels of vitamin K have been associated with 




other factors associated with skeletal complications in liver disease
Pro-inflammatory cytokines, such as IL-1 and TNF-alpha, are increased in patients 
with liver cirrhosis and stimulate osteoclast activity and thereby bone resorption. 
Hyperhomocysteinemia may occur in patients with liver disease as a result of 
stimulation of the hepatic production of homocysteine by a number of factors 
such as nutritional vitamin deficiencies and cigarette smoking or because of 
accumulation of the protein due to reduced excretion in case of renal impairment. 
Hyperhomocysteinemia has been associated with increased risk for fractures 
independently of BMD, possibly by altering bone quality through abnormal collagen 
crosslinking.
effect of underlying liver disease on the skeleton
Alcoholic liver disease
Alcohol abuse is associated with decreased bone mass and increased fracture risk.
(67-70) Ethanol exerts direct toxic effects on osteoblasts, resulting in decreased 
bone formation.(71) In addition, ethanol also stimulates osteoclast activity through 
stimulating the RANK/RANK-L system.(72;73) Ethanol also alters the metabolism of 
several hormones, including vitamin D, IGF-1 and cortisol. In alcoholics, malnutrition may 
also contribute to bone loss when alcohol represents the main caloric intake.(74) Heavy 
alcohol intake is also associated with increased risk of falls and thereby increased risk of 
fracture.(75)
Cholestatic liver disease
Cholestasis, as seen in cholestatic liver diseases such as primary biliary cirrhosis 
(PBC), primary slerosing cholangitis (PSC) and overlap syndromes with auto-immune 
hepatitis (AIH), negatively influences vitamin D metabolism.(32;34;35) A decrease in 
bile salts availability is associated with defective absorption of dietary vitamin D when 
transportation of bile salts to the intestine is compromised.(32;34;35) In patients with 
PSC a concomitant inflammatory bowel disease, such as Crohn’s disease, may in its 
own right contribute to decreased intestinal re-absorption of bile salts and vitamin 
D through mucosal inflammation or surgical resection of significant length of the 
small intestine to control disease activity.(35) In addition to the effect of cholestasis on 
absorption of vitamin D, cholestatic toxins may also directly influence bone remodeling 
through an effect on the RANK/RANKL pathway and on mediators of osteoblast 
function, thus contributing to decreased bone formation and increased bone resorption 




Chronic hepatitis B and C infections (HBV and HCV) have been reported to be associated 
with bone loss, regardless of their effect on liver function (78-81). High bone turnover 
and increased bone resorption have been observed in viral liver diseases possibly related 
to the inflammatory process associated with increased levels of cytokines, leading 
to stimulation of the RANK/RANKL pathway and of all aspects of osteoclastogenesis. 
Higher levels of soluble tumor necrosis factor (TNF) receptor-55 have also been shown to 
be associated with increased bone resorption and lower BMD in patients with HCV.(81) 
Fracture rate has also been shown to decline after virus clearance.(82) Antiviral therapy 
used to treat viral hepatitis may also affect bone turnover. Ribavirin has been shown to 
impair osteoblast proliferation, with one study showing lower BMD in patients treated 
with this agent (83), although this deleterious effect of this antiviral agent on bone is 
controversial, as other studies have showed stable or increasing BMD during ribavirin 
therapy.(84-86)
Iron storage disease
In haemochromatosis, an autosomal recessive disease with a HFE-gene mutation 
leading to increased iron absorption due to inappropriate hepcidin secretion (87), iron 
excess is associated with low bone mass and increased risk of fractures.(38;40;88;89) 
The main mechanism of action of iron overload is to impair osteoblast activity.(38-40) 
Iron overload may also contribute to the development of central hypogonadism due to 
pituitary iron deposition, with associated increased bone resorption and decreased bone 
formation.(38-40)
sKeletal comPlications after liver transPl antation
Bone loss and fractures are common after solid organ transplantation, including liver 
transplantation, and these skeletal complications are associated with significant 
morbidity and mortality. The pathogenesis of these skeletal complications remains 
incompletely understood. Corticosteroids and other drugs used for immunosuppression 
play an important role. Main additional contributing factors include the underlying 
primary liver pathology and skeletal status at the time of transplantation. Potential 
other contributing factors include persistent vitamin D deficiency and hypogonadism or 
high bone turnover.
Significant bone loss at the lumbar spine (LS) as well as the femoral neck (FN) occurs 
during the first six months after liver transplantation with a more variable course 
thereafter. (90-98) Fracture incidence is very high despite recovery of liver function, 
with new fractures occurring in 15-34% of patients within the first year after OLT, mainly 
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1vertebral and rib fractures.(1-4) LS BMD has been shown to spontaneously recover thereafter, reaching pre-transplant values within two years after OLT.(4;99-103) FN 
BMD has been reported to remain low in most studies, with BMD stabilizing or even 
decreasing further beyond the first year after OLT.(4;102;104;105)
underlying liver disease
Significant differences in degree of bone loss and in fracture incidence have been 
reported after OLT according to type of liver disease (2;102;103;105;106;106-108), with 
patients with cholestatic liver disease being at higher risk for fractures than patients 
with other liver diseases.
underlying skeletal pathology
Low bone mass and fractures are already highly prevalent before liver transplantation. 
Osteoporosis is thus reported in 15-40% of patients with end-stage liver disease 
(94;95;107;109;110) and fractures are reported to be prevalent in 6-30% of 
patients(107;111-113). Whereas pre-existing low bone mass is a risk factor for fractures 
after transplantation (1;2;4;114-116), fractures have also been shown to occur in patients 
with osteopenia or normal bone mineral density (BMD).
corticosteroids
Corticosteroids are used postoperatively in almost all immunosuppressive protocols 
after solid organ transplantation. Corticosteroids exert their deleterious effects on 
bone through direct and indirect effects on bone cells, mainly leading to suppression 
of bone formation, but also to a certain extent by increasing bone resorption, with the 
resulting bone loss being more prominent at trabecular sites. The mechanism bone 
of loss due to corticosteroids is complex. Glucocorticoids lead to osteoblast apoptosis 
and to suppression of osteoblast differentiation by suppression of markers genes such 
as Run2x and Wnt/beta catenin signaling, leading to decreased bone formation.(117) 
On the other hand, glucocorticoids also induce bone resorption by reducing osteoclast 
apoptosis, resulting in net bone loss. Glucocorticoids also indirectly contribute to bone 
loss by reducing intestinal calcium absorption and increasing urinary calcium excretion. 
Vitamin D metabolism does not appear to be influenced by glucocorticoids.(118) 
Corticosteroids also decrease the stimulatory effect of IGF-1 on osteoblasts. The effect of 
glucocorticoids on bone have been shown to be dose dependent (4;105;119), which may 
explain the bone loss and increased fractures risk observed in liver transplant recipients 




A number of immunosuppressive agents may also have adverse effects on bone with 
a tendency for calcineurin inhibitors such as cyclosporine or tacrolimus to cause rapid 
and profound bone loss.(120;121) High bone turnover and increase in bone turnover 
markers of bone formation and resorption have been demonstrated in experimental 
animal studies of calcineurin use (122) and also confirmed by histomorphometric studies 
of bone biopsies, with greater bone loss shown with tacrolimus than with cyclosporine 
A.(123) However, data on the effects of calcineurin inhibitors in humans are scarce and 
results are conflicting.(124-126) Several studies have shown a less deleterious effect of 
tacrolimus on bone compared to cyclosporine A. A histomorphometric study showed 
earlier recovery of bone turnover after OLT in patients treated with tacrolimus compared 
to those treated with cyclosporine A (127), which was confirmed by two other studies, 
showing less bone loss in patients treated with tacrolimus and an earlier recovery of 
bone mass to pre-transplant values.(128;129) Small subgroup analysis in one study (114) 
and an observational study (130) indeed show that incident fractures occur less in OLT 
recipients treated with tacrolimus compared to cyclosporine A. In contrast, another 
study showed no difference in bone mass between cyclosporine A and tacrolimus 
treated patients. (131) Taken together, these conflicting data suggest that the exact 
effect of tacrolimus on the skeleton remains to be established in patients with a liver 
transplantation. Mycophenolate mofetil (MMF) has not been shown thus far to have 
a deleterious effect on bone.(125;129) Data on the effect of sirolimus on bone turnover 
are conflicting, with studies showing increased as well as decreased osteoclast activity.
(132;133)
renal failure
A decline in renal function is common after OLT and this may contribute to further bone 
loss.(94;96;100;134) During the early post-operative period, acute kidney injury occurs 
in up to 64% of patients.(135) Pre-existing renal impairment and comorbidity lead to 
increased susceptibility to kidney injury. Several factors may lead to acute kidney injury 
after transplantation, including acute tubular necrosis, calcineurin inhibitor toxicity and 
sepsis. In the long-term, some degree of chronic renal impairment is highly prevalent in 
OLT recipients. One study showed a prevalence of moderate renal impairment in over 
50% of OLT recipients at twenty years after OLT (136), and the cumulative incidence 
of renal failure (glomerular filtration rate of 29 ml/ minute/ 1.73m2 body surface 
or less) is reported to be 18% at five years after OLT.(137) As previously mentioned, 
renal impairment contributes to bone loss and to mineralization disorders due to 






Recovery of liver function leads to reversal of cholestasis and reversal of metabolic 
disturbances early after transplantation. IGF-1 and IGFBP-3 levels increase rapidly after 
OLT, normalizing within the first week after successful transplantation.(60;62;138) 
Gonadal hormones have been shown to increase (4;100;139) and 25(OH)D levels 
normalize in the majority of patients(100;104;134;139;140). The introduction of new 
immunosuppressive regimens has allowed early tapering of corticosteroids (141-145), 
substantially contributing to recovery of bone mass.
Vitamin D deficiency
Even though vitamin D status improves after OLT, as shown by post-transplantation 
increases in 25(OH)D (100;100;104;134;139;140), vitamin D levels do not normalize 
in all patients, and a degree of vitamin D deficiency persist in a number of patients. 
Furthermore, even though 25(OH)D levels increase after transplantation, this does not 
always translate in increases in the metabolically active calcitriol.(4;100)
Persistent hypogonadism
Gonadal function improves after transplantation, with marked increases in free 
testosterone levels observed within the first year after OLT.(4) However, recovery 
to normal levels is not achieved in all patients, with hypogonadism persisting in a 
substantial proportion of OLT recipients.(4;100;139)
theraPeutic considerations
In solid organ transplantation, prevention of post-transplantation bone disease involves 
optimization of pre-transplant skeletal health and prophylaxis of post-transplantation 
bone loss. Patients with end-stage liver disease should be screened for skeletal 
pathology and treated accordingly. Life-style measures, including cessation of smoking 
and of alcohol use, good nutrition and weight bearing exercise, are to be advised to all 
patients. Calcium and vitamin D should be adequately supplemented where required. 
Vitamin D deficiency should be corrected to levels above 50 nmol/L, using follow-up 
measurements of 25(OH)D. This is the level suggested by the Institute of Medicine (146) 
although the International Osteoporosis Foundation (IOF) suggests a higher threshold 
of 75 nmol/L for men and women above the age of 60 and those with osteoporosis (147). 
It is to be noted that in clinical practice, it is sometimes difficult to reach the threshold 
of 75 nmol/L with the recommended daily use of 800 units of colecalciferol. At the 
moment, there is still no consensus on the desirable cut-off point of 25(OH)D to reach 
in liver transplant recipients but in view of the important role of the liver in vitamin 
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D metabolism, it remains highly recommended to measure these 25(OH)D levels in 
patients with chronic liver disease before and after liver transplantation.
bisphosphonates
Most studies showed a short-term beneficial effect of bisphosphonate treatment on 
BMD when treatment is initiated at or shortly after OLT.(148-155) Bisphosphonates 
used in these studies were largely nitrogen-containing bisphosphonates including 
intravenously administered zoledronate, ibandronate and pamidronate (148-150;154-163) 
and orally administered alendronate and risedronate (149;151-153). Time of initiation 
of treatment was at or shortly after OLT in most studies (148-152;154-157;162), and 1-2 
years after OLT in 3 studies(158;161;163) and patients were usually treated for one year 
(148-150;152;155-157;161) or 2-3 years (151;153;158;163). Most studies showed a decrease of 
biochemical markers of both bone formation, including procollagen type 1 N-terminal 
propeptide (P1NP), bone alkaline phosphatase and osteocalcin, and of those of bone 
resorption, including beta crosslaps (CTX) and urinary deoxyhydroxyproline, after 
initiation of treatment with bisphosphonates in some (148;151;152;155;158;163) but not 
all studies.(149;150;157;160) A decrease in bone turnover was also demonstrated in two 
bone histomorphometry studies.(156;162) The authors of a meta-analysis published in 
2011 concluded that bisphosphonate treatment administered during the first year after 
OLT appeared to reduce accelerated bone loss and to improve LS BMD.(164) Data on 
long-term effect of treatment with bisphosphonates administered shortly after OLT on 
BMD are scarce and conflicting, with two studies showing a persistent beneficial effect 
on BMD (150;153), whereas this was not confirmed in a second study.(157) Three studies 
in which treatment was initiated after the first year after OLT show a beneficial effect 
on BMD.(158;161;163) Treatment with bisphosphonates in the form of pamidronate 
administered as a single infusion before OLT did not prevent post-transplantation 
bone loss.(160) Data on both short-term and long-term effect of bisphosphonate 
treatment on fracture risk are conflicting, with studies showing a decreased fracture 
incidence in treated patients with oral as well as intravenous bisphosphonates, initiated 
before, at or shortly after and 1-2 years after OLT and for a duration of 9-24 months 
(149;150;152;153;158;159), whereas other studies did not show any effect on fracture risk.
(151;154;157;160;163) In the only published meta-analysis, the effect of bisphosphonate 
treatment on fracture risk could not be analysed because of heterogeneity of the 
available data.(164)
Whereas bisphosphonates have thus been shown to reduce post-transplantation 
bone loss and to some degree fracture risk in most but not all studies, there is still 
no consensus on which patients should be treated with these agents. Antiresorptive 
therapy should be considered in patients with low bone mass particularly in the 
presence of fractures. However, since pre-transplant BMD poorly identifies patients at 
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1risk for fractures, and these have been shown to occur in patients with normal BMD (2;114;165), the question raised is whether all liver transplant recipients should be 
treated with antiresorptive agents at time of transplantation.
conclusion
The metabolic and excretory functions of the liver play an important role in normal 
bone remodeling. In liver diseases, disturbances in both physiological functions of the 
liver are associated with loss of bone mass as well as bone quality, leading to increased 
fracture risk. Significant bone loss occurs after liver transplantation despite recovery of 
the metabolic and excretory functions of the liver, mainly due to immunosuppressive 
regimens including glucocorticoids. The incidence of new fractures is also very high 
during the first year after liver transplantation, with fractures occurring in up to a third 
of transplant recipients, leading to significant morbidity and to a decrease of quality 
of life. The aetiology of bone loss and increased fracture risk observed in OLT recipients 
is multifactorial and still incompletely understood. It has thus been proven difficult to 
identify patients at risk. Moreover, data on efficacy of bisphosphonate treatment after 
liver transplantation are scarce and heterogeneous.
Awareness of the magnitude of skeletal pathology in patients with liver disease 
remains a clinically unmet need before and after liver transplantation. Candidates for 
liver transplantation and patients with liver diseases need to be thoroughly screened 
for low bone mass and prevalent fractures and disturbances in calcium and mineral 
homeostasis need to be adequately corrected in order to prevent further bone loss and 
decrease post-transplantation fracture risk.
Questions to be addressed
Mechanisms leading to bone loss in patients with end-stage liver disease need to be 
further elucidated. Since immunosuppressive regimen have changed during the last 
decade with the introduction of new immunosuppressive agents and early tapering 
of corticosteroids, the magnitude of bone loss and fracture risk in OLT recipients 
under current transplantation protocols needs to be re-examined. Risk factors for 
post-transplantation bone loss and fractures need to be elucidated in order to identify 
patients at risk. The value of bone turnover markers, BMD measurements and prevalent 
fractures in the identification of patients at risk need to be examined. Furthermore, 
the optimal time of initiation of treatment, the modality of treatment and its duration 
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remain to be established in OLT recipients. Finally, it needs to be clarifiede whether the 
persistent high fracture rate a year after OLT may be decreased or prevented.
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liver transplant recipients at time of 
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Context: Osteoporosis and fractures are prevalent after orthotopic liver transplantation 
(OLT), but data on these skeletal complications are scarce in patients with end-stage 
liver disease awaiting liver transplantation.
Objective: To evaluate the prevalence of vertebral fractures (VF) in OLT recipients at time 
of screening for transplantation and establish the association between bone mineral 
density (BMD) and these fractures before transplantation
Design and setting: Retrospective study of consecutive OLT recipients at the 
Leiden University Medical Centre between 2000 and 2011 at time of screening for 
transplantation. Clinical, laboratory and BMD data were extracted from electronic 
hospital records. Conventional spinal radiographs were assessed for VF by two 
independent observers using the Genant’s semi-quantitative method.
Patients: In total, 162 of 223 OLT recipients (median age 51 yrs, 75% men)who had 
available BMD and spinal radiographs but who were not receiving bone-modifying 
treatment at screening for OLT were included in the study.
Results: Osteoporosis and osteopenia were prevalent in respectively 19 and 38% at the 
lumbar spine and in 10 and 42 % at the femoral neck. VF mostly grade 1 were prevalent in 
56% . There was no association between BMD and prevalent VF before transplantation.
Conclusions: Vertebral fractures are prevalent in liver transplant recipients at time of 
screening for transplantation, but there was no association between BMD and prevalent 
fractures. Spinal radiographs should be routinely performed as part of screening 
protocols before liver transplantation to enable identification of VF and allow timely 
intervention to potentially decrease or prevent skeletal morbidity after transplantation
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introduction
Osteoporosis and fractures are common after liver transplantation (1-3), but data on 
these skeletal complications are scarce in patients with end-stage liver disease, awaiting 
orthotopic liver transplantation (OLT).(2;4-6) Published data suggest low bone mass 
in over 50% of patients, and prevalent vertebral fractures varying from 3.5% to 36% 
of patients before transplantation, depending on the method used for identification 
of these fractures.(1;4;5;7;8) The liver plays an important role in bone and mineral 
metabolism. The aetiology of bone loss and increased fracture risk associated with 
disturbed liver function is multifactorial, including vitamin D deficiency, hypogonadism, 
decreased mobility, corticosteroid use (in autoimmune hepatitis) and alcohol toxicity 
where relevant. Candidates for liver transplantation with underlying skeletal pathology 
are potentially at higher risk for skeletal morbidity, particularly increased fracture risk, 
after transplantation.(1;2;9) Cholestatic liver disease has been reported to be associated 
with osteoporosis and vertebral fractures (10-12), and alcohol abuse is a common cause 
of osteoporosis and increased fracture risk, particularly in men (5;13) but less is known 
about these skeletal complications in other liver pathologies.
Prevalent vertebral fractures represent an important predictive factor for future 
fractures.(1;2;14) Data indeed show that risk of future fracture significantly increases 
with increasing number and/or grade of severity of vertebral fractures, also shown to 
be true for mild grade 1 vertebral fractures. (15) Identification of these fractures before 
transplantation would thus be of significant clinical relevance, not only to predict future 
fracture risk, but also to allow timely initiation of therapeutic interventions potentially 
able to decrease or prevent skeletal morbidity after transplantation.
The main objectives of our study were to evaluate the prevalence of vertebral 
fractures in liver transplant recipients at time of screening for transplantation, and 




Consecutive patients who underwent a first OLT at the Leiden University Medical Centre 
between January 2000 and January 2011, and who had available BMD measurements 
and conventional radiographs of the thoracic and lumbar spine, performed at the 
time of their extensive in-hospital screening program before liver transplantation, 
were eligible for inclusion in the study. Patients treated with corticosteroids or 
bisphosphonates before or at time of screening for transplantation were excluded from 
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the present analysis because of the bone-modifying nature of these therapeutic agents. 
The Leiden University Medical Centre is a tertiary referral centre for liver diseases, and 
our first encounter with the majority of patients is often only at time of screening for 
liver transplantation. Correction of vitamin D deficiency and treatment of osteoporosis 
with bone-modifying agents such as bisphosphonates has thus been very variable 
despite clear guidelines, and highly dependent on the clinical judgement of the referring 
physician, rather than dictated by a specific protocol.
methods
Demographic, clinical, laboratory and BMD data at time of screening before liver 
transplantation were obtained from individual patients electronic hospital records. 
Availability of conventional spinal radiographs was ascertained from the records. 
Non-vertebral fractures were poorly documented so that data on these fractures could 
not be analyzed.
1. Demographic data
Data on age, gender, smoking, height, weight and primary liver disease were 
documented. Data on medication including use of corticosteroids, calcium- and vitamin 
D supplements and bone modifying agents such as bisphosphonates were recorded.
2. Biochemical investigations
Biochemical data extracted from the patients’ records included serum calcium, 
corrected for an albumin of 40 g/L, phosphate, creatinine, total bilirubin, anticoagulant 
international normalized ratio (INR), parathyroid hormone (PTH) and 25-hydroxy-
vitamin D (25-OHD) concentrations. Severity of liver disease was determined using 
the laboratory-based Model for End-stage Liver Disease (MELD) score, shown to be 
correlated with 3-month survival in patients with end-stage liver disease. Scores were 
calculated on the basis of serum measurements of bilirubin, creatinine and INR in SI 
units, using the following accepted formula (16):
MELD = 10 * (0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43
3. Bone mineral density measurements
Bone mineral density (BMD) was measured at the lumbar spine (LS) and at the femoral 
neck (FN) using dual energy X-ray absorptiometry (Hologic QDR 4500, Hologic inc. 
Waltham, MA, USA, equipped with reference values based on the National Health 
and Nutrition Examination Survey (NHANES III)). Data collected included absolute 
measurements of BMD in g/cm2 , T-scores (standard deviation above or below that of a 
young adult reference population at peak bone mass) and Z-scores (standard deviation 
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above or below that of an age- and sex matched reference population). World Health 
Organization (WHO) criteria were used to define osteoporosis: T-score of -2,5 or less and 
osteopenia: a T-score between -1 SD and -2.5 SD.
Due consideration was given to the need to adjust mean BMD scores of the LS in 
the presence of one or more lumbar vertebral fractures at the site of the LS BMD 
measurement (L1-L4).
4. Vertebral fracture assessment
Conventional anterior-posterior and lateral radiographs of the thoracic spine and 
postero-anterior and lateral radiographs of the lumbar spine were performed by an 
experienced radiology technician using a standardized protocol, at a distance of 115 cm, 
with the film centralized on Th7 for the thoracic spine and on L3 for the lumbar spine.
All radiographs were blindly assessed for the presence and severity (grade) of 
vertebral fractures by two independent observers, an experienced musculoskeletal 
radiologist (H.K.) and an experienced bone and mineral disorders specialist ( N.H.). 
Fractures were assessed using the Genant’s semi-quantitative method of vertebral 
fracture assessment.(17) Using this method, a decrease in height of 20-25% is considered 
to be a “mild” grade 1 fracture, a decrease of 25-40% a “moderate” grade 2 fracture 
and a decrease of > 40% a “severe” grade 3 fracture. Uniform loss of vertebral height 
compared to adjacent vertebrae were additionally documented using the same 
grading scores. Radiographs were assessed in a random order, using random numbers 
generated by SPSS software (version 20). A unique number was assigned to each series 
of radiographs performed at screening for OLT. Radiographs were individually scored 
by the two independent observers and in case of discrepancy in scores, mostly about 
fracture grading, consensus was achieved by both observers reviewing the radiographs 
together. Careful attention was given to the interpretation of vertebral deformities, 
excluding vertebral height reductions or deformities due to development abnormalities, 
degenerative changes, osteochondritis, (Scheuermann’s disease) or localised metabolic 
bone disorders such as Paget’s disease of bone.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre.
statistical analysis
For descriptive statistics, categorical variables were expressed as numbers and as 
percentages. Data containing continuous variables were summarized using mean and 
standard deviation in case of an estimated normal distribution. Median and 5th and 95th 
percentiles were used otherwise.
A regression model was used to evaluate the influence of potential risk factors for the 
development of osteoporosis and for the prevalence of vertebral fractures. A univariate 
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regression model was first used, followed by a multivariate regression model with 
corrections for multiple variables including age and sex. A linear regression model 
was used in case of continuous variables and a logistic regression model in case of 
dichotomous variables.
We chose to calculate odds ratios rather than risk ratios because of the regression 
models used. A p-value < 0.05 was considered significant.
We evaluated the direct effect of various risk factors, such as cholestatic or alcoholic 
liver disease, on the outcome parameter, such as prevalence of fractures, as well as the 
indirect effect of the risk factor on the outcome of through various mediators, such 
as vitamin D deficiency, using a logistic regression model. We calculated confidence 
intervals of the effect of mediators using the bootstrap method.
Calculations were performed using STATA/SE 12.0 software (StataCorp LP, TX, USA).
results
Patients characteristics
In total, 162 of the 201 patients, who received an elective OLT in the 10-year period 
between 2000 and 2011, who had available BMD measurements and conventional spinal 
radiographs performed at the time of screening before liver transplantation but who 
were not treated with bisphosphonates, corticosteroids or other bone-modifying agents 
were included in the study. Of the 39 excluded patients, 21 had for logistics reasons no 
Total population 
screened for LT  
2000-2011  
(n= 429) 
Elective LT  
(n = 201) 
BMD  +  
spinal X-rays 
(n=180) 




Included in the study 
Bone modifying treatment 
(n=18) 
 - Bisphosphonates (n=8) 
 - Corticosteroids (n=7) 
 - CS+ bisphosphonates (N=3) 
Excluded 






(n = 60) 
 *high urgency 
 *auxillarytransplantation 
 *incomplete data   
Excluded 
No transplantation  
(n= 168) 
 
 * Death (n= 66) 
 * Deterioration (n=52) 
 * Improvement (n= 50) 
Not analyzed 
 
Figure 1: Study Flow Chart; LT = liver transplantation; BMD = bone mineral density; CS = corticosteroids
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BMD measurements and/or conventional spine radiographs at time of screening for OLT, 
and 18 patients were using bone modifying treatments. Details of patients included and 
excluded are shown in a Study Flow Chart (Figure 1). Median age for the total population 
studied was 51 years (range 17-69 years), and 122 of the 162 patients were men (75%). 
Median age for women was also 51 years (range 16 - 66), and 23 women were younger 
than 50 years. Menopausal status was not documented. Most common liver pathology 
was viral or alcoholic liver disease (31 and 29% respectively), followed by cholestatic liver 
disease (14%). 8% of patients were using calcium and vitamin D supplements, usually as 
a combination preparation at a fixed dose of 500mg calcium and 400 IU cholecalciferol, 
which had been initiated at some stage before screening for transplantation. Details of 
patients’ characteristics are shown in Table 1.
biochemical data
Mean serum creatinine concentration was 89 ± 47 µmol/L (normal < 104 µmol/L). 
Median bilirubin level was 32 µmol/L (range 4-1172, normal < 17 µmol/L). Mean INR was 
Table 1 Characteristics of patients at time of screening for liver transplantation
Demographic data
No of patients 162
Male – no of patients (%) 122 (75%)
Age at the time of screening- Median (5th - 95th percentile), years 51 (30-65)
BMI – mean (SD), kg/m2 26 ± 5
Smoking – no of patients (%) 54 (35%)
Primary liver disease – no of patients (%)
Viral 50 (31%)
Alcoholic 47 (29%)
Combined alcoholic and viral 4 (2%)
Cholestatic (PSC / PBC/ overlap syndrome) 22 (14%)
Malignancy 8 (5%)
Auto-immune hepatitis 4 (2%)
Metabolic 5 (3%)
Othera 22 (14%)
Severity of liver disease- mean lab MELD-score ± SD 14 ± 6
Bone-specific medication – no of patients (%)
Calcium- and vitamin D supplements 12 (8%)
Vitamin D supplements 2 (1%)
aOther primary liver disease including cryptogenic cirrhosis, malignant tumor, vascular, rare metabolic 
disorders; BMI = body mass index; SD = standard deviation; OLT = orthotopic liver transplantation; PSC 
= primary sclerosing cholangitis; PBC = primary biliary cirrhosis; LS = lumbar spine; FN = femoral neck. 
MELD = Model for End-stage Liver Disease.
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1.3 ± 0.33. Mean 25-OHD level was 32 ± 23 nmol/L (normal 50-250 nmol/L). 25-OHD levels 
were also low, with a mean of 31 ± 24 nmol/L in patients using vitamin D supplements. 
Of the 162 patients studied 110 patients had 25-OHD levels < 50 nmol/L, of whom 54 
patients had levels of < 25 nmol/L. Mean laboratory MELD-score, reflecting severity of 
liver disease, was 14 ± 6 SD (range 6-35).
bmd measurements
Osteoporosis and osteopenia were prevalent in respectively 19 and 38 % of patients at 
the LS, and in 11 and 42% of patients at the FN. Mean T-score was -1.15 ± 1.44 at the LS and 
-1.06 ± 1.23 at the FN. Mean Z-score was -0.63 ± 1.49 at the LS and -0.15 ± 1.21 at the FN. 
Distribution of BMD at the LS and FN are shown for men and women in Figure 2.
factors associated with a low bmd
We evaluated a number of potential risk factors for low BMD at time of screening for 
transplantation (Table 2). Age and gender were not associated with increased risk for 
osteoporosis. Cholestatic liver disease was associated with significant increased risk for 
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Figure 2 Distribution of bone mineral density in 40 women (upper panel) and 122 men (lower panel) 
with end-stage liver disease awaiting liver transplantation.
Middle, upper and lower lines represent respectively mean, + 1 and -1 standard deviation of an age and 
sex matched reference population; FN = femoral neck; LS = lumbar spine; BMD = bone mineral density.
47
BMD and fractures before liver transplantation
2
not in the multivariate model. There was no indirect effect of cholestatic liver disease 
through vitamin D deficiency on low bone mass. (OR 1.00, 95%CI 0.96-1.05). Compared 
to other liver pathologies, alcoholic liver disease was not associated with an increased 
risk for low bone mass at the LS in the multivariate model (OR 0.27, 95%CI 0.08-0.87, 
p=0.028), an effect independent of smoking (OR 1.02, 95%CI 0.98-1.06). Severity of liver 
disease as reflected by the laboratory MELD-score, was associated with an increased risk 
of low bone mass at the FN in both the univariate and multivariate model (multivariate 
model: OR 1.15, 95%CI 1.02-1.29, p = 0.021), but not at the LS. Vitamin D deficiency (25-
OHD levels < 25 nmol/L) was associated with an increased risk for osteoporosis at the LS 
in the univariate model (OR 1.16, 95%CI 1.01-1.32, p =0.029), but not in the multivariate 
model or at the FN.
Prevalence of radiographic vertebral fractures
We documented 186 vertebral fractures in 90 patients, representing a prevalence of 
56%. 43 patients (44%) had one prevalent fracture, 25 had two fractures (15%), and 22 
had three or more fractures (14%). Over 50% of patients had one or more mild grade 
1 fracture (52%), of whom eleven patients (10%) also had moderate grade 2 fractures. 
None of the patients studied had severe grade 3 vertebral fractures. The anatomical 
distribution of the fractures is shown in Figure 3; 47 patients had lumbar vertebral 
Table 2 Risk factors for osteoporosis
Risk factor
Univariate Multivariate
LS Osteoporosis FN Osteoporosis LS Osteoporosis FN Osteoporosis


















































































fractures, of whom 32 had one fracture, 24 of which of the first lumbar vertebra. Five 
patients had 2 lumbar fractures, 2 patients 3, and 2 patients had fractures of all 4 
lumbar vertebrae. The majority of these fractures were single grade 1 fractures, with no 
significant impact on total LS BMD, so that they were not excluded from the analysis of 
total BMD.
Mid-thoracic compression fractures, usually involving 2-3 vertebrae, most commonly 
thoracic vertebrae 7 to 9, were prevalent in 7 patients (6%).
factors associated with radiographic vertebral fractures
We found no significant relationship between BMD and prevalent vertebral fractures 
using either univariate or multivariate analysis. In patients with prevalent fractures, 38% 
had a normal BMD, 40 % had osteopenia and only 23% had osteoporosis. There was no 
significant association between BMD as a continuous variable, the presence or absence 
of low BMD, and the presence or absence of vertebral fractures, number of fractures per 
individual patient or grade of severity of the fractures.
Male gender was associated with a higher prevalence of vertebral fractures than 
female gender, with an odds ratio of 4.10 (95% CI 1.73-9.67, p = 0.001), independently 
of age, underlying disease pathology or severity of liver disease as expressed by the 
laboratory MELD score (Table 3). Age as a continuous parameter, vitamin D status, 
underlying liver disease and severity of liver disease were not associated with an 































Figure 3 Distribution of 186 vertebral fractures in 90 patients with end-stage liver failure awaiting liver 
transplantation; Th = thoracic vertebra, L= lumbar vertebra.
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discussion
Our data from this retrospective cohort study suggest a high prevalence of vertebral 
fractures, mostly grade 1 fractures, in 56% of liver transplant recipients at time of 
screening for transplantation, independently of BMD measurements, although low 
bone mass, predominantly osteopenia, was documented in about two thirds of these 
patients. At time of screening for liver transplantation, there was, thus, no association 
between BMD as a continuous variable or the presence or absence of low BMD and the 
presence or absence of vertebral fractures, higher number of fractures per individual 
patient or higher grade of fractures. Of all factors other than BMD potentially associated 
with increased fracture risk, only male gender was associated with increased fracture 
prevalence, independently of age, underlying liver disease or severity of liver failure. The 
absence of a significant association between BMD and fracture prevalence suggests 
that factors affecting bone quality, rather than just bone quantity, may significantly 
contribute to fracture risk in patients with end-stage liver failure.
Our findings are in keeping with previously published studies, which report low 
bone mass in over 50% of patients awaiting liver transplantation, with the majority 
having osteopenia and 20-40% osteoporosis.(2;5;7;8;10;11;18-21) A high prevalence of 
osteoporosis and fractures reported in patients with cholestatic liver disease (10-12) is 
believed to be due to vitamin D deficiency and/or to the toxic effects of accumulated 
metabolites of cholestasis on bone remodelling. In our cohort, cholestatic liver disease 
also represented an increased risk for osteoporosis at the FN and for prevalent vertebral 
fractures in univariate but not multivariate analysis. We did not observe an increased 
prevalence of vertebral fractures in patients with alcoholic liver disease, possibly 
because of the removal of the inhibitory effect of alcohol on osteoblast function 
by the prerequisite alcohol abstinence for at least six months prior to screening for 
Table 3 Risk factors for vertebral fractures
Risk factor
Univariate Multivariate
OR (95%CI) P-value OR (95%CI) P-value
Male gender 1.36 (1.14-1.62) 0.001* 4.10 (1.73-9.67) 0.001*
Age (years) 1.02 (0.99-1.06) 0.136 1.03 (0.99-1.07) 0.093
Smoking 0.91 (0.77-1.08) 0.266 0.64 (0.30-1.38) 0.256
Cholestatic liver diseases 0.76 (0.61-0.95) 0.016* 0.33 (0.10-1.12) 0.076
Alcoholic liver disease 1.07 (0.86-1.42) 0.443 0.80 (0.35-1.86) 0.607
Lab MELD-score 1.01 (0.96-1.07) 0.712 1.03 (0.96-1.11) 0.361
LS BMD (g/cm2) 1.34 (0.21-8.21) 0.755 0.78 (0.10-5.96) 0.808
* significant effect, p –value <0.05; MELD = Model for End-stage Liver Disease; BMD = bone mineral 
density; LS = lumbar spine
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transplantation, which may have also contributed to the improvement in BMD at time 
of screening.(22)
The high prevalence of vertebral fractures of 56% observed in our cohort at time 
of screening before transplantation is much higher than the overall prevalence of 
fractures of 7% observed in a recent Dutch population-based cohort of men and 
women aged > 55 years, in which all subjects were screened by conventional spinal 
X-rays.(23) The observed prevalence of vertebral fractures in our study was also 
higher than that of previously published studies, which showed a widely variable 
and overall lower prevalence of these fractures (3 to 36%), in patients awaiting liver 
transplantation (1-3;5;7;8;19;24). The main reason for this discrepancy in prevalence of 
vertebral fractures between our study and that of others probably lies in the method 
used for the identification of these fractures. Since vertebral fractures are often silent, 
actual fracture prevalence may have been underestimated in studies in which spinal 
radiographs were only performed in case of clinical suspicion of a vertebral fracture.
(5;8;25;26) In contrast, conventional radiographs of the spine formed an integral part 
of the pre-transplantation work-up of our candidates for liver transplantation, and 
were consequently available in all but a few patients. In our study, we also judged it 
of clinical relevance to report grade 1 fractures, whereas mild grade fractures might 
have been underreported in previous studies. This is partly because radiologists have 
been generally reluctant worldwide to report mild vertebral fractures, so that relying 
on radiology reports for documentation of these fractures may have resulted in an 
underestimate of their true prevalence.(27;28) Mild grade fractures may have also been 
consciously underreported because of doubt about their clinical relevance, although 
these mild fractures have also now been shown to be associated with increased fracture 
risk.(15)
The relationship between BMD and prevalent fractures has been poorly studied in 
patients awaiting liver transplantation, and available data are not concordant. Some 
studies thus show an association between low BMD and prevalence of vertebral 
fractures (1;29), but other studies found no such association.(3;30) In our study, there 
was intriguingly no association between BMD as a continuous variable or as low 
vs normal BMD and fracture prevalence. 33% of patients with fractures had thus 
normal BMD and 35% had osteopenia, suggesting that factors affecting bone quality 
independently of BMD may significantly contribute to increased skeletal fragility in 
patients with advanced liver disease. This may have significant implications in the 
management of skeletal complications of advanced liver disease before and after liver 
transplantation, as tools to measure bone quality in vivo such as micro-indentation are 
just emerging and remain to be validated, and data on means to specifically improve 
bone quality with a view to decrease fracture risk are as yet to be established.
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Notwithstanding, the accurate identification of prevalent vertebral fractures is 
essential in fracture risk assessment, as these fractures represent one of the strongest 
predictor of subsequent vertebral and non-vertebral osteoporotic fractures.(31;32) 
There is also evidence that mild-grade 1 vertebral fractures are also predictive for future 
fracture risk.(15) Of further clinical relevance is that up to 50% of vertebral fractures, 
even high grade ones, may be asymptomatic (33), and not necessarily associated with a 
decrease in BMD, so that they may not come to the attention of treating physicians. The 
small number of patients treated with bisphosphonates despite the high prevalence of 
osteoporosis and vertebral fractures and the overall poor vitamin D status of patients 
awaiting liver transplantation underscores the clinically unmet need for treating 
physicians to address the issue of skeletal health in patients with end-stage liver 
disease.
Our study has strengths as well as limitations. Its major strength lies in the evaluation 
of consecutive transplant recipients at time of screening for transplantation, in one 
center, over a 10-year period, providing a representative pre-transplantation cohort, 
with available BMD measurements and conventional radiographs of the spine in all 
but a few patients. Another strength of our study is the blinded assessment of all 
spinal radiographs for vertebral fractures by two experienced independent observers 
using the Genant’s standardized semi-quantitative method advocated by the 
International Osteoporosis Foundation (IOF) for evaluation of vertebral fractures in 
the clinic (34), rather than relying on routinely obtained radiology reports shown to 
often underestimate the true prevalence of fractures. (25) In most other studies in liver 
transplantation so far reported, (semi-)quantitative assessments were performed by one 
observer (1;7;29;30) or the method of evaluation of vertebral fractures is not mentioned 
(5;6;19;35). A further strength of our study is the inclusion of the mild grade 1 vertebral 
fractures in the evaluation of prevalent fractures.
A limitation of our study is its retrospective study design. However, the laboratory, 
radiological and densitometric investigations were not randomly undertaken, but 
formed an integral part of a pre-planned pre-transplantation screening protocol for 
skeletal complications, performed in patients with end-stage liver failure, who in this 
case went on to receive a liver transplantation. Although most candidates for liver 
transplantation were screened for skeletal complications, we only studied those who 
subsequently received a liver transplant, which may have led to an underestimate of 
the true prevalence of skeletal pathology, since the excluded patients would have been 
more likely to have had the more severe liver disease and thus potentially the more 
severe skeletal complications. We also chose to exclude patients using corticosteroids 
and /or bisphosphonates, which could have also led to the exclusion of patients with 
the worst skeletal pathology. However, since this was the case in a relatively small 
number of patients, this is unlikely to have affected the outcome of our study. The 
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absence of prior spinal radiographs precluded the identification of the precise time of 
occurrence of a documented fracture, resulting in the association between BMD and 
prevalent fractures being potentially limited by the time lag between the development 
of a fracture and BMD measurement. We could collect no reliable data on non-vertebral 
fractures, as these were poorly documented. However, previous studies report a 
generally low incidence of these fractures in end-stage liver disease.(2;5;6;8;19;29)
In conclusion, our finding of increased fracture risk independently of BMD in liver 
transplant recipients at time of screening for transplantation, adds to the accumulating 
body of evidence of the contributory role of bone quality rather than just bone 
quantity to fracture risk in patients with liver disease. This finding has significant 
clinical implications in the evaluation and management of prospective liver transplant 
recipients, as it suggests that spinal radiographs should be routinely performed in these 
patients to enable identification of vertebral fractures and thus of skeletal fragility. 
Whether this pre-transplantation skeletal fragility persists, worsens or improves after 
liver transplantation, and whether bone fragility could be modulated by available 
bone-modifying agents to decrease or prevent skeletal morbidity after transplantation 
remains to be established by long-term studies specifically addressing the issue of 
skeletal health in liver transplant recipients.
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Introduction Osteoporosis is prevalent in end-stage liver disease, but data on long-term 
changes in bone mineral density (BMD) and related fracture incidence are scarce after 
orthotopic liver transplantation (OLT).
Method We evaluated BMD changes up to 5 years in consecutive recipients of a 
successful OLT at the Leiden University Medical Centre between 2000 and 2011, in 
whom sequential BMD data were available. Spinal radiographs, available at time of 
screening and at six and twelve months post-OLT, were assessed for vertebral fractures 
by two independent observers using Genant’s semi-quantitative method. Patients were 
excluded when started on bisphosphonates.
Results 201 patients (71% men), median age 53 years (range 18-70 years) were included 
in the study. Most common liver pathology was viral (27%) or alcoholic liver disease 
(25%). All patients received prednisone for at least 6 months after transplantation 
and the majority either tacrolimus or cyclosporine for immunosuppression. At time of 
screening for OLT, osteoporosis and osteopenia were found in respectively 18 and 36 % of 
patients at the lumbar spine (LS) and in respectively 9 and 42 % at the femoral neck (FN). 
T-scores declined significantly at both sites 6 months after OLT, but increased thereafter 
at the LS, reaching pre-transplant values at 2 years, and remaining stable thereafter. 
FN T-scores remained consistently lower than pre-transplant values. The prevalence of 
vertebral fractures increased from 56% at screening to 71% at one year after OLT, with a 
fracture incidence of 34%. BMD changes did not predict fracture risk.
Conclusion Osteoporosis, osteopenia and vertebral fractures are prevalent in patients 
with end-stage liver disease. An overall decline in BMD is observed within the first 6 
months after OLT, with subsequent recovery to pre-transplant values at the LS, but not 
at the FN. Vertebral fracture risk is high after OLT regardless of changes in BMD.
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introduction
Osteoporosis is reported to be prevalent in end-stage liver disease, and accelerated 
bone loss associated with increased fracture risk has been observed in 25-35% of 
patients in the first twelve months after orthotopic liver transplantation (OLT).(1-11) 
The initial decline in bone mineral density (BMD), believed to be predominantly due 
to corticosteroid use for immunosuppression, is generally followed by a stabilization 
in bone mass between 6 and 12 months after OLT, with no further decrease in 
BMD thereafter, independently of the use of bone-modifying agents such as 
bisphosphonates.(1;3-6;8;9;12) Data on natural changes in BMD beyond the first year 
after OLT are scarce, however, and mainly based on small studies, or on studies in 
patients with exclusive cholestatic liver disease as underlying liver pathology.(1-9;12-16) 
Studies had also been performed over a decade ago (1-5;13-15), before the introduction 
of currently used immunosuppressive regimens, which enable the use of significantly 
lower corticosteroid doses post-OLT, thus precluding exposure to a high cumulative 
dose of these agents. Whether the spontaneous recovery of BMD within the first year 
after OLT is also associated with a decreased fracture risk has also not been adequately 
addressed.
The aims of this study were to examine changes in BMD after OLT in a cohort of 
consecutive liver transplant recipients not receiving treatment with anti-resorptive 
agents, to identify risk factors for bone loss after successful OLT and to examine the 
influence of changes in BMD on fracture risk within the first year after OLT.
Patients and methods
Patients
Consecutive patients who underwent a first OLT at the Leiden University Medical 
Centre between January 1st 2000 and January 1st 2011, and who had sequential 
bone mineral density (BMD) measurements after OLT, were eligible for the study, 
including 20 patients who had BMD measurements from 6 months onwards after OLT. 
Immunosuppressive regimens for OLT consisted of corticosteroids for at least 6 months 
in all patients, with an additional calcineurin inhibitor: cyclosporine or tacrolimus in 
the majority, with mofetil mycophenolate (MMF) or sirolimus as additional second 
or third immunosuppressive agent in a few. International guidelines concerning 
immunosuppression were complied with in the case of new transplanted patients, 
but established immunosuppressive regimen were not routinely altered in individual 
transplant patients. Corticosteroid schedules included methylprednisolone at a dose 
of 500 mg given during the OLT procedure, followed by oral prednisolone at a dose 
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of 20 mg daily for one week, 10 mg daily for 3 months, slowly tapering to complete 
discontinuation of corticosteroids between 3 and 6 months after OLT in all but a 
few patients who required maintenance doses of prednisolone of 2.5 – 10 mg/day. 
Treatment with calcium- and vitamin D supplements in a combined fixed dose of 500 
mg elemental calcium and 400 IU colecalciferol, and treatment with bisphosphonates 
were initiated at the discretion of the treating physician. Patients treated with 
bisphosphonates before or at time of screening for OLT were excluded from the study. 
Patients receiving bisphosphonates after OLT were censored and thus excluded from 
further analysis from time of starting treatment.
methods
Demographic and clinical data
Patients’ demographic and clinical data were obtained from electronic hospital records. 
Data on age, gender, smoking, height, weight and primary liver disease were collected. 
Concomitant or later renal transplantation was documented. Data were also collected 
on date and cause of death. Recorded medication included immunosuppressives, 
calcium and vitamin D supplements and bone-modifying medication such as 
bisphosphonates.
Laboratory investigations
Laboratory data were also obtained from electronic hospital records. Biochemical 
data collected included serum calcium, corrected for an albumin of 40 g/L, phosphate, 
creatinine, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25-OHD) 
concentrations, which were measured at screening for OLT and at various time points 
thereafter. Severity of liver disease was determined using the laboratory- Model for 
End-stage Liver Disease (MELD) scores(17) calculated on the basis of serum creatinine, 
bilirubin and INR measurements obtained at time of screening for OLT. The following 
accepted formula was used to calculate the scores:
MELD = 10 * (0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43
Bone mineral density measurements
Bone mineral density (BMD) was measured at the lumbar spine and at the femoral 
neck using dual energy X-ray absorptiometry (DXA- Hologic QDR 4500, Hologic inc. 
Waltham, MA, USA, equipped with reference values based on the National Health and 
Nutrition Examination Survey (NHANES III)). Absolute measurements of BMD in g/
cm2 as well as T-scores (matched to young adult reference populations at peak bone 
mass) and Z-scores (age- and sex-matched reference populations) were recorded. World 
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Health Organization (WHO) criteria were used to define osteoporosis (T-score of -2.5 
SD or less) and osteopenia (T-score between -1 SD and -2.5 SD). BMD measurements 
were performed at time of screening for OLT (baseline), at 6 and 12 months post-OLT, 
and yearly thereafter for up to 60 months after OLT. BMD measurements at 36 and 48 
months post-OLT were not analyzed because too few measurements were available at 
these time points.
Vertebral fracture assessment
Spinal radiographs were routinely performed at time of screening and at six and twelve 
months after OLT. Conventional antero-posterior and lateral radiographs of the thoracic 
spine and postero-anterior and lateral radiographs of the lumbar spine were performed 
by an experienced radiology technician following a standardized protocol, at a distance 
of 115 cm, with the film centralized on Th7 for the thoracic spine and on L3 for the lumbar 
spine.
All conventional radiographs of the thoracic and lumbar spine were blindly assessed 
for the prevalence and individually scored for the severity (grade) of vertebral fractures 
by two independent observers, an experienced musculoskeletal radiologist (H.K.) and 
an experienced bone and mineral disorders specialist ( N.H.). Vertebral fractures were 
assessed using the Genant’s semi-quantitative method.(18) Using this method, a 
decrease in height of 20-25% is considered to be a “mild” grade 1 fracture, of 25-40% a 
“moderate” grade 2 fracture and of > 40% a “severe” grade 3 fracture. Uniform loss of 
vertebral height compared to adjacent vertebrae was additionally documented using 
the same grading scores. Radiographs were assessed in a random order, using random 
numbers generated by SPSS software (version 20, SPSS inc., Chicago, IL, USA). A unique 
number was assigned to each series of radiographs. In case of discrepancy in scores, 
consensus was achieved by both observers reviewing the radiographs together.
Laboratory, BMD and fracture data collected at time of screening for OLT were 
considered to be baseline data.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre.
statistical analysis
For descriptive statistics, categorical variables were expressed as numbers and as 
percentages. Continuous variables were summarized using mean and standard 
deviation in case of normal distribution of data; median and 5th and 95th percentiles were 
used otherwise. An extension of a Generalized Linear Model, Generalized Estimation 
Equations (GEE), was used for calculation of differences in laboratory measurements and 
BMD, to account for repeated measurements. Patients treated with bisphosphonates 
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were excluded from time of initiation of treatment for the duration of follow-up. 
Incidence rates for osteoporosis after OLT (number of new cases/person years at risk) 
were calculated with follow-up time starting after transplantation. Patients already 
diagnosed as having osteoporosis at time of screening for OLT were not included in the 
calculation of osteoporosis incidence. An incident fracture was defined as the occurrence 
of a new vertebral fracture or an increase in grade of a prevalent fracture between serial 
radiographs before and during the first year after OLT. Follow up duration until incident 
osteoporosis, or last measurement of BMD, was used to calculate person-years at risk. 
GEE model was used to evaluate the influence of various factors on changes in BMD, 
corrected for age and gender and accounting for repeated measurements.
Prevalence of fractures was calculated by dividing the number of patients with 
at least one vertebral fracture by the total number of patients with available spinal 
radiographs. A GEE model was used to evaluate the influence of change of BMD on 
fracture risk, corrected for age and gender and accounting for repeated measurements. 
A univariate and multivariate logistic regression model was used to evaluate risk factors 
for incident fractures.





Nine of the 223 eligible transplant recipients were not included in the study because 
bone densitometry data were not available after OLT and thirteen patients were also 
not included because of treatment with bisphosphonates before or at time of screening 
for OLT.
Of the 201 patients included in the study, 142 were men (71%). Median age at time 
of OLT was 53 years (range 18-70 years, with only 4 patients being younger than 20 
years). The most common primary liver diseases were viral hepatitis (27%) and alcoholic 
liver disease (25%), followed by cholestatic liver disease (14% ) (Table 1). At time of 
screening for OLT, 9 patients (5%) were using corticosteroids, and calcium- and vitamin D 
supplements were prescribed as combination treatment to 21 patients (10%).
Laboratory data
Mean creatinine level was 92 ± 67 µmol/L (normal < 104 µmol/L). Mean vitamin D level 
was 32 ± 23 nmol/L (normal 50-250 nmol/L), 125 patients (83%) had 25-OHD levels < 50 
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Table Demographic data at time of screening and after liver transplantation
Demographic data
Number of patients 201
Gender – number of male patients (%) 142 (71%)
Age at the time of OLT- Median (range), years 53 (18-70)
Death during follow-up – no of patients (%) 34 (17%)
Time of death after OLT – Median (5th - 95th percentile), month 10 (1-57)
BMI – mean (SD), kg/m2 26 (5)
Smoking – number of patients (%) 64 (34%)
Primary liver disease – number of patients (%)
Viral 54 (27%)
Alcoholic 51 (25%)
Combined alcoholic and viral 4 (2%)
Cholestatic (PSC / PBC/ overlap syndrome) 29 (14%)
Malignancy 12 (6%)
Auto-immune hepatitis 10 (5%)
Metabolic 7 (3%)
Other* 34 (17%)
Previous or concomitant renal transplantation
- number of patients (%) 6 (3%)
Time between screening and OLT
- median (5th – 95th percentile), months 9 (1-27)
Second OLT
- number of patients (%)
- time to second OLT – median (5th – 95th percentile), days
28 (14%)
165 (2-1064)
Rejection episodes – number of episodes (cumulative incidence, %)
6 months after OLT 27 (14%)
12 months after OLT 30 (15%)
24 months after OLT 42 (22%)
60 months after OLT 42 (22%)
Calcium – and vitamin D supplements at time of screening– - number of patients (%) 21 (10%)
Bisphosphonates after OLT - number of patients (%)
12 months 58 (32%) 
24 months 66 (43%) 
60 months 42 (48%) 
Corticosteroids at time of screening - number of patients (%) 9 (5%)
Immunosuppressive medication initiated at OLT
- number of patients (%)
Prednisone, tacrolimus 88 (44%)
Prednisone, cyclosporine 44 (22%)
Prednisone, cyclosporine and MMF 21 (10%)
Prednisone, tacrolimus and MMF 18 (9%)
Other 30 (15%)
OLT = orthotopic liver transplantation; BMI = body mass index; PSC = primary sclerosing cholangitis; PBC = pri-
mary biliary cirrhosis; LS = lumbar spine; FN = femoral neck; MMF = mycofenolate mofetil. * including crypto-
genic cirrhosis, Budd-Chiari syndrome, portal vein thrombosis, hereditary polycystic liver-disease, acute liver 
failure of pregnancy, medically induced cirrhosis, Caroli disease, cystic fibrosis, Rendu-Osler-Weber’s disease.
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nmol/L, 87 of whom had levels of <30 nmol/L. Mean bilirubin level was 79 ± 140 mmol/L 
(normal < 17 mmol/L).
Severity of liver disease
Severity of liver disease at screening for OLT, as expressed by laboratory-MELD score, 
could be calculated in 196 of the 201 patients (98%). Mean score was 14 ± 6 (range 6-35).
BMD data
BMD measurements were available in 181 patients at time of screening for OLT, but 
technically non- evaluable in 11 patients at the lumbar spine. Evaluation was precluded 
in these 11 patients by the presence of residual oral contrast material from abdominal 
CT-scans, required as part of the screening protocol for OLT, but chronologically 
performed by error before DXA. Osteoporosis and osteopenia were respectively found 
in 18% and 36% of patients at the lumbar spine (LS) and in 9 and 42 % of patients at the 
femoral neck (FN).
Fracture data
176 patients had available conventional spinal radiographs at time of screening for OLT. 
99 patients (56 %) had one or more vertebral fractures, mostly grade 1 fractures (87%). 
Of the patients with documented prevalent vertebral fractures, 20 had osteoporosis 
(22%), 38 osteopenia (42%) and 41 had a normal BMD (36%).
b. data after olt
Clinical data
Median time between screening and OLT was 9 months (range 0-66 months, 5th – 95th 
percentile 1-27 months). All patients received prednisone during the first 6 months 
after OLT. Prednisone was combined with tacrolimus in 44% of patients or with 
tacrolimus and MMF in 9% of patients. Cyclosporine was given to 22% of patients and 
combined with MMF in 10% of patients. Rejection episodes occurred mainly in the first 
six months after OLT (27 patients) with a cumulative incidence of 22% at five years 
after OLT. A second OLT was performed in 28 patients (14%) after a median time of 7 
months (range 0-37 months). Calcium and vitamin D supplements were increasingly 
prescribed after OLT with 26 patients (14%) receiving these agents at screening, 107 
(58%) at one year after OLT and 68 patients (77%) at 5 years after OLT. Within the first 
year after OLT, bisphosphonate treatment was initiated in 58 patients (32%), and 42 
patients (48%) were using these agents at 5 years after OLT. Median time of initiation of 
bisphosphonates was 12 months after OLT (range 12-48 months).
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Six patients (3%) received a previous or concomitant renal transplantation. Thirty 
four patients (17%) died during the follow-up period, at a median time of 10 months 
after OLT (range 1 – 58 months). The most common cause of death was infection (n=7) 
and recurrence of hepatocellular carcinoma (n=5). Other causes included myocardial 
infarction, hypoglycemia and suicide.
Laboratory data
There was a significant improvement in liver function tests with time after OLT, with 
mean bilirubin level decreasing from 78 ± 141 mmol/L at screening to 20 ± 35 mmol/L 
(p < 0.005) at twelve months and to 20 ± 60 mmol/L at two years after OLT (p < 0.005), 
stabilizing thereafter with bilirubin levels of 15 ± 13 mmol/L at 5 years after OLT. There 
was a mild but significant decrease in renal function after OLT, with mean creatinine 
level increasing from 92 ± 67 µmol/L at time of screening for OLT to 113 ± 50 µmol/L at 12 
months after OLT (p< 0.005), stabilizing thereafter with mean creatinine level of 111 ± 66 
µmol/L at five years after OLT. Mean vitamin D levels increased from 32 ± 23 nmol/L at 
time of screening to 51 ± 28 nmol/L at twelve months after OLT (p < 0.005) and to 60± 29 
nmol/L at five years after OLT (p < 0.005).
Changes in BMD after OLT
Sequential changes in BMD were analyzed in the 201 patients included in the study. 
BMD measurements were not available at screening in 20 of these patients but 
sequential data were available from six months onward after OLT. BMD declined 
significantly at both LS and FN sites between screening and six months after OLT: LS 
-0.02 g/cm2 (– 2.5%), p =0.002; FN -0.05 g/cm2 (-6.5%), p <0.005), stabilizing thereafter 
until 12 months after OLT (Figure 1). Between one and two years after OLT, LS T-scores 
increased by 1.2 % (0.02 g/cm2, p = 0.012), reaching pre-transplant values at two years 
after OLT and subsequently remaining stable. In contrast, FN BMD remained consistently 
below pre-transplantation values, but after the initial significant loss demonstrated 
no further decline up to 5 years of follow-up (Figure 1). A second OLT did not influence 
the course of changes in BMD. Incidence rates of osteoporosis at the LS and FN were 
respectively 4.2 and 4.7 per 100 person-years after OLT. The cumulative incidence of 
osteoporosis at the lumbar spine was 7% at six months, 12.1 % at twelve months and 
14.7% at five years (Figure 2). The cumulative incidence of osteoporosis at the femoral 
neck was 8.5 % at six months, 10.5% at twelve months and 19.5% at five years after OLT.
Incidence of fractures after OLT
Spinal radiographs were available and evaluable in 115 patients at six months and in 106 
patients at twelve months after OLT. The prevalence of fractures increased from 56% at 
time of screening to 78 out of 115 patients (68%) at six months after OLT, and to 75 out 
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of 106 patients (71%) at twelve months after OLT. Incident fractures occurred in 45 out 
of 133 patients (34%) in whom a second spinal radiograph was available during the first 
year after transplantation.
c. risk factors for bone loss and for vertebral fractures after olt
We studied the effect of age, gender, primary liver disease, severity of liver disease, BMD 
at screening for OLT and immunosuppressive regimens, including corticosteroids, on 
bone loss and fracture risk within the first year after OLT. Of these potential risk factors 
which may influence BMD, the only ones with a significant relationship with bone loss 
were age 52 years or older in women (pragmatic cut-off age for menopause) (OR 0.89, 
95%CI 0.81-0.99, p=0.0024), and the use of the calcineurin inhibitor tacrolimus for 
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Figure 1: Changes in LS and FN T-scores in patients not treated with bone-modifying agents after OLT. 
# = Significant decrease p < 0.05 compared to values at the time of screening; * = Significant increase 
p < 0.05 when compared to values at 12 months after OLT; LS = lumbar spine; FN = femoral neck; OLT = 
orthotopic liver transplantation.
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predictive for bone loss either at the LS (OR 0.95, 95%CI 0.90-1.01, p=0.080) or at the FN 
(OR 0.99, 95%CI 0.95-1.04, p=0.674). Patients with alcoholic liver disease demonstrated 
an increase, rather than a decrease, in LS but not FN BMD after OLT (at LS OR 1.08, 95% CI 
1.02-1.14, p = 0.005; at FN OR 1.03, 95% CI 0.99-1.08, p =0.187).
Of the potential risk factors studied, only male gender (OR 5.15, 95%CI 1.41-18.8, p 
= 0.013), and higher age (OR 1.06, 95%CI 1.00-1.11, p = 0.045) were associated with an 
increased risk for incident fractures. Other factors, including cholestatic liver disease, 
severity of liver disease, lumbar spine BMD and prevalent fractures at time of screening 
for OLT, were not predictive for increased fracture risk after OLT. There was no relationship 
between immunosuppressive medication and fracture risk . There was no difference in 
pattern of change in BMD at the LS or FN in patients with incident vertebral fractures 
within the first year after OLT compared to those who did not sustain a fracture (LS BMD: 
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Figure 2: Incidence of osteoporosis. Kaplan Meier survival curve showing the proportion of patients 
without osteoporosis at the LS (upper panel) and FN (lower panel) after OLT. LS = lumbar spine, FN = 




Our findings from this study of longitudinal changes in BMD and vertebral fracture 
incidence in a cohort of recipients of an orthotopic liver transplantation show a high 
prevalence of osteopenia/ osteoporosis and vertebral fractures at time of screening for 
OLT. 54% of patients with diverse primary liver pathology had thus some degree of bone 
loss and 56% had prevalent vertebral fractures. Despite the high prevalence of skeletal 
pathology in these patients with end-stage liver disease awaiting liver transplantation, 
only a few received treatment with a bisphosphonate, which provided us the unique 
opportunity of studying sequential changes in BMD and fracture risk in a relatively large 
number of OLT recipients not receiving bone-modifying treatment. In keeping with 
previously published studies, with up to 2 years follow-up after OLT (1-3;7;9;10;12;13;16), 
we observed significant bone loss at both the LS and FN sites between screening and 6 
months after OLT. Spontaneous recovery of BMD to pre-transplant values was observed 
at the LS within two years after OLT, with our longer term data showing stabilization 
of LS BMD thereafter for up to five years after OLT. In contrast to the increase in BMD 
observed at the lumbar spine after the initial rapid post-OLT decline in BMD, there 
was no similar recovery of BMD at the femoral neck. Data on long-term changes in FN 
BMD after OLT are scarce and not always concordant.(1;5;9;13) Whereas some studies 
show an increase in FN BMD during the second year after OLT (1;5), other studies show 
a persistently low FN BMD compared to pre-transplant values, or a further decline in 
bone mass at cortical sites.(6;9;13;15;16) The discrepancy in behavior of BMD between 
LS and FN sites is likely to be due to the difference in proportion of trabecular and 
cortical bone between these two sites. Trabecular bone comprises 66 % of total bone 
at the vertebrae, whereas cortical bone comprises >75% of the total bone composition 
of the femoral neck. Trabecular bone is much more susceptible to changes in the bone 
microenvironment resulting from disease processes than cortical bone, just as it is 
more readily susceptible to pharmacologic interventions. BMD at the LS thus shows 
the greatest magnitude and speed of change in response to reversal of diseases 
processes as well as to pharmacological interventions such as has been repeatedly 
demonstrated with the use of anti-resorptives or anabolic agents in the management 
of osteoporosis. After successful OLT, reversal of cholestasis, of vitamin D deficiency and 
of hypogonadism, which follow the restoration of liver function, is likely to significantly 
contribute to the spontaneous improvement in LS BMD, with recovery of FN BMD 
lagging behind that of LS BMD up to 5 years after OLT.
Corticosteroids form the mainstay of the induction and maintenance of 
immunosuppression after solid organ transplantation, and these agents are used in 
nearly all immunosuppressive protocols. An association between corticosteroid use and 
early post-transplantation bone loss has been observed in the early stages of solid organ 
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transplantation.(8) However, the introduction of new immunosuppressive regimens 
has allowed the early tapering of corticosteroids, thereby substantially contributing 
to recovery of bone mass in the long-term after transplantation. Nonetheless, acute 
rejection episodes occur more commonly in the first 3 months after transplantation, so 
that corticosteroids withdrawal is only practical thereafter.
In our study, only few of the risk factors evaluated at screening for OLT, which may 
potentially influence BMD, were able to predict bone loss or its severity post-OLT. 
Alcoholic liver disease was interestingly, but perhaps not surprisingly, associated with 
no decrease in BMD after OLT. Alcohol is toxic to the osteoblast and alcohol abuse is 
associated with a low turnover osteoporosis. Alcohol withdrawal is a prerequisite for 
liver transplantation, and candidates for OLT have to be completely dry for at least 
six months before being eligible for transplantation. In transplant recipients with 
alcoholic liver disease, removal of the toxic effect of alcohol on the osteoblast before 
transplantation, in addition to the improvement in nutritional status, when alcohol does 
no longer represent the major source of caloric intake, could well explain the lack of 
deterioration of bone mass after OLT in patients with this liver pathology.
We found no relationship between graft function, corticosteroid use, number of graft 
rejection episodes or persistent vitamin D deficiency on the degree of bone loss after 
OLT. This is also in keeping with data from a number of studies addressing the role of 
these factors on post-OLT bone loss.(1;3;4;8;9;12-14), although some other studies did 
find an association between cholestatic liver disease, cumulative prednisone dose and 
bone loss after OLT.(5;6;8)
Previously published data on fracture incidence after OLT show wide variability, 
ranging from 10-33% within the first year after OLT.(5;7;9;11;14;15;19) Our data on 
one-year fracture incidence are in keeping with only one previously published study, 
in which a semi-quantitative method of evaluation of vertebral fractures on routinely 
performed conventional spinal radiographs was also used, and the evaluation was 
performed by two independent observers on sequential radiographs.(9) Another reason 
for the discrepancy in fracture incidence between our study and that of others may 
be that previous studies were performed in smaller number of patients (5;9;14;15;20), 
or in patients solely with cholestatic liver disease as primary liver pathology.(19) 
Furthermore, although conventional spine radiographs were performed in some 
studies, these were not evaluated by semi-quantitative methods, which may have also 
led to underestimation of fracture incidence since routine radiology reports tend to 
underreport specially mild grade fractures.
Data on risk factors for incident fractures after OLT are conflicting. BMD-
measurements have been found to be predictive in some studies (9;14;15;19), but 
not in others (7;11). In our study, both BMD at time of screening as well as changes 
of BMD within the first year after OLT were not predictive for fracture risk. Whereas 
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some studies showed prevalent fractures before OLT to be associated with increased 
fracture risk after transplantation (11;19;20), this was not the case in our study. These 
data suggest that the absence of low bone mass and of prevalent fractures before OLT 
does not preclude an increased risk for fracture after transplantation so that it is of 
significant clinical relevance that liver transplant recipients should be regularly screened 
for the presence of these fractures and treated accordingly.
Our study has a number of strengths as well as limitations. Its main strength lies 
in the relatively large representative cohort of patients studied, the availability of 
sequential BMD measurements as only inclusion criterion, providing a minimal selection 
bias, and the opportunity to study changes in BMD for a relatively long period after 
OLT without the confounding influence of bone-modifying treatment on BMD. Another 
strength of our study is the availability of serial spinal radiographs within the first year 
after transplantation in a large number of patients, and the blinded semi-quantitative 
assessment of all spinal radiographs for vertebral fractures by two experienced 
independent observers.
Our study has also a number of limitations. There were no pre-defined treatment 
protocols for immunosuppressive regimens, or for indication for bisphosphonate 
therapy. These patient management decisions were left to the clinical judgment of 
the treating physician and may have provided some degree of bias. Another limitation 
may be our choice to exclude patients from the time of initiation of bisphosphonate 
treatment, using ‘last observation carried forward’ to minimize the effect of this 
censoring on our data. Since patients excluded from further analysis because of starting 
therapy were most likely to have continuing bone loss if left untreated, the increase 
in BMD reported in the remaining untreated patients may have been overestimated, 
although numbers of patients treated are smaller than those of untreated patients. 
Since treatment with different immunosuppressive regimens was not randomly 
assigned, effect of these regimens on patterns of bone loss after OLT could also not be 
compared. A further limitation of our study is the variable time lag between screening 
for OLT and date of transplantation. Since the median time between screening and 
OLT was 9 months, it is conceivable that further bone loss and new fractures may 
have occurred between screening and transplantation, with possible further decrease 
in liver function and worsening cholestasis potentially contributing to worsening of 
skeletal pathology. However, this limitation is common to most published studies 
with the majority failing to report time lag between pre- and post-transplantation 
measurements.(1-5;7;12-14) Although the heterogeneity of the population studied 
may be perceived as a limitation, we did not consider this to be the case, as the 
distribution of primary liver pathology was fairly representative of OLT populations, 
patients receiving bisphosphonates were excluded from the analysis and patients 
receiving a second liver transplant did not have a different course of changes of BMD. 
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Only 12 patients (6%) were using corticosteroids at screening and use of these agents 
post-transplantation would override the effect of the pre-transplantation use of these 
agents.
In conclusion, osteopenia, osteoporosis and vertebral fractures are prevalent in 
prospective liver transplant recipients. An overall decline in BMD is observed within 
the first 6 months after OLT, with subsequent spontaneous recovery to pre-transplant 
values at the LS, but not at the FN up to five years after OLT. The incidence of vertebral 
fractures is high within the first year after OLT with poor association between 
pre-transplantation factors, changes of BMD and fracture risk. Whereas our findings 
do highlight the spontaneous recovery of BMD associated with restoration of liver 
function, and its maintenance in the long-term after liver transplantation, our data 
also demonstrate that the spontaneous recovery in BMD was not associated with a 
corresponding decrease in fracture risk, at least within the first year after orthotopic 
liver transplantation, suggesting a potentially persistent or irreversible effect of liver 
disease on bone quality and fracture risk. Whether treatment with bisphosphonates or 
other bone-modifying agents may be able to decrease or prevent fracture risk within 
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Introduction Osteoporosis and fractures are common in chronic liver disease and 
fracture incidence increases after orthotopic liver transplantation (OLT). The value of 
bone turnover markers (BTMs) in the prediction of bone loss and fracture risk pre- and 
post-OLT remains unclear.
Study design The BTMs P1NP, osteocalcin, BALP and CTX were measured de novo or in 
Biobank stored serum at screening and at 3, 6 and 12 months post-OLT in consecutive 
OLT recipients between 2008 and 2011. A prerequisite for inclusion was the availability of 
BMD data and of spinal radiographs at screening and 6 and 12 months post-OLT.
Results 51 patients (80% male, median age 59 yrs) were studied. Most common liver 
pathology was alcoholic (41%) and viral liver disease (26%). At screening, osteoporosis 
and osteopenia were prevalent in respectively 16 and 33 % at the lumbar spine (LS) 
and in 4 and 44% at the femoral neck (FN). Prevalence of vertebral fractures was 67%. 
Post-OLT, LS BMD remained stable but FN BMD decreased and 43% of patients developed 
new fractures. At screening, serum P1NP and CTX levels were high and osteocalcin levels 
were low. Only CTX levels were predictive for bone loss and fracture risk. An increase in 
BALP post-OLT was predictive for fracture risk a year post-OLT.
Conclusion Despite the many pitfalls in the interpretation of particularly collagen-
derived BTMs in liver disease, persistently high CTX levels pre- and post-OLT and an 
increase in BALP post-OLT were predictive for bone loss and/or fracture risk during the 
first post-OLT year.
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introduction
Osteoporosis is prevalent in 20-50% of patients with chronic liver disease awaiting 
orthotopic liver transplantation (OLT) (1-9), and prevalent vertebral fractures have 
been reported in 3.5-36% of these patients. (1;2;8-11) After OLT, accelerated bone loss 
of multifactorial aetiology further increases fracture risk, leading to new vertebral 
fractures in 14-30% of patients within the first year after OLT.(2;5;6;8;11-13) It has been 
proven difficult, however, to identify factors predictive for increased fracture risk in liver 
transplant recipients. The association between clinical parameters, such as primary liver 
pathology or severity of liver disease, or of bone mineral density (BMD), and fracture risk 
has thus been shown to be inconsistent and generally poor.(5;9;12-17)
Over the past two decades, there has been increasing interest in the use of bone 
turnover markers (BTMs) in the prediction of bone loss and of fracture risk, and in the 
monitoring of the efficacy of treatment of osteoporosis with bone modifying agents 
particularly in postmenopausal women.(18-21) BTMs are biochemical products of 
bone remodelling, which reflect the metabolic activity of bone. Alterations in bone 
remodelling are in turn associated with changes in bone microarchitecture and 
increased fracture risk. BTMs are released in the circulation where they can be measured 
in serum, and excreted by the kidneys, when they can be measured in urine.
In patients with chronic liver disease, there has been considerable heterogeneity of 
data on indices of bone remodelling particularly when set against data from the gold 
standard histomorphometric analysis of bone biopsy specimens obtained mostly before 
and within the first 6 months after OLT. Reported BTM data suggest no increase in bone 
turnover (15;22-24), or increased bone turnover particularly increased bone resorption 
before transplantation (4;25-28). Findings after transplantation suggest increased bone 
turnover, particularly bone resorption in the early post-transplant period.(15;17;24;29) In 
2011, the International Osteoporosis Foundation (IOF) and the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC) have issued a Position Paper 
recommending the use of serum procollagen type I N-terminal propeptide (P1NP) as the 
preferred bone formation marker, and of the cross-linked C-terminal telopeptide of type 
I collagen (CTX) as the preferred bone resorption marker in clinical studies, in patients 
with osteoporosis, also supporting a role for BTMs in the prediction of fracture risk 
independent of BMD in postmenopausal women and in the monitoring of treatment.
(30) However, the position paper also underlined that the clinical value of BTMs remains 
somewhat limited by amongst other causes the inadequate appreciation of the sources 
of variability of these markers. Interpreting data on bone turnover markers represents 
an even greater challenge in patients with liver disease as collagen type I is produced 
and degraded at increased rates in patients with liver fibrosis as previously reported by 
Guanabens et al in 22 patients with primary biliary cirrhosis.(31) Data on BTMs before 
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and in the short-term after OLT are conflicting (3;32-37), and there are no long-term data 
on sequential changes in BTMs after OLT.
The aim of our study was to assess the value of BTMs in the prediction of bone loss 
and fracture risk within the first year after OLT in a well characterized population of 
liver transplant recipients in whom sequential BTMs, BMD data and conventional spinal 
radiographs were available before and during the first year after liver transplantation.
Patients and methods
Patients
Consecutive patients who underwent a first OLT at the Leiden University Medical Centre 
between January 1st 2008 and January 1st 2011 and who had available BTM measurements 
(either directly measured or measured from stored sera) at time of screening for 
OLT were eligible for inclusion the study. Excluded were patients who were treated 
with bisphosphonates, and those who received a second OLT or a renal transplant 
during the study period. The date of January 1st 2008 for start of the study was 
selected because of the availability of P1NP measurements in our Clinic from this time 
onwards. A period of alcohol abstinence of at least six months was a prerequisite for 
screening for OLT in patients with alcoholic liver disease. Post-OLT immunosuppressive 
regimens consisted of corticosteroids for at least 6 months in all patients, combined 
with a calcineurin inhibitor: cyclosporine or tacrolimus in the majority, with mofetil 
mycophenolate (MMF) or sirolimus as additional second or third immunosuppressive 
agent in a few. Basiliximab was administered in the anhepatic phase and on day four 
after transplantation. Corticosteroid schedules included methylprednisolone at a dose 
of 500 mg given twice during the OLT procedure, followed by oral prednisolone at a 
dose of 20 mg/day for one week, 10 mg/day for 3 months, slowly tapering to complete 
discontinuation of corticosteroids between 3 and 6 months after OLT in all but a few 
patients who required maintenance doses of prednisolone of 20-40mg/day in divided 
doses. Treatment with calcium and vitamin D supplements at a combined fixed dose of 
500 mg elemental calcium and 400 IU cholecalciferol was initiated in the majority of 
patients at some stage after OLT.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre.
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methods
Demographic and clinical data
Demographic and clinical data were obtained from the patients’ electronic hospital 
records. Data on age, gender, smoking, height, weight and primary liver disease were 
collected. Medication including immunosuppressive agents, calcium and vitamin D 
supplements and bone-modifying medication such as bisphosphonates was recorded. 
Data were also collected on date and cause of death.
Biochemical investigations
Laboratory data were obtained from the patients’ electronic hospital records. 
Biochemical data collected included serum calcium, corrected for an albumin of 40 g/L, 
phosphate, creatinine, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)
D) and P1NP concentrations, which were measured at screening for OLT and at 3, 6 and 
12 months after OLT. Normal values were < 104 µmol/L for creatinine levels, 50-250 
nmol/L for 25-vitamin D levels, < 17 mmol/L for bilirubin levels. Data on serum creatinine, 
bilirubin and INR obtained at screening for OLT were used to calculate the MELD score 
reflecting severity of liver disease before transplantation, using the following formula:
MELD = 10 * (0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43
In patients in whom P1NP measurements were not available, this was retrospectively 
measured from stored sera using the same Electro-Chemo-Luminescence Immunoassay 
(ECLIA) on a Modular E170 immunoanalyzer (Roche Diagnostics, Mannheim, Germany) 
with an analytical variation of 6%. Serum stored at – 80° was made available from 
the Liver Transplantation Biobank for missing measurements of P1NP, and for the 
measurement of the bone turnover markers: osteocalcin, bone-alkaline phosphoatase 
(BALP) and CTX at screening before OLT and when available at 3, 6 and 12 months after 
OLT. Stored serum for the measurement of CTX was obtained in the non-fasting state. 
BALP was measured by enzyme-linked immunosorbent assay (ELISA; Metra Biosystems, 
Mountain View, CA, USA; inter-assay coefficient of variation (CVinter) 5.5%), osteocalcin 
by immunoradiometric assay (IRMA; BioSource Europe S.A; CVinter 9.4%), and CTX by 
electrochemiluminescence immunoassay (ECLIA; Elecsys 2010 Roche Mannheim, 
Germany; CVinter  10.8%). Serum samples were stored within one hour of collection at 
-20ºC until analysis was performed. BTM Z-scores, the number of standard deviations 
(SD) from the normal mean corrected for age and gender, were calculated using a Dutch 
control reference group (200 men and 350 women aged >= 50 years) checked with 
laboratory confirmed serum 25-hydroxyvitamin D levels >= 50 nmol/L and no evidence 
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for osteoporosis (BMD T-score >-2.5) on DXA evaluation. BTM Z-scores were calculated as 
follows:
Z-score = (BTM value of individual patient – mean BTM value of reference group) / SD of 
matched reference cohort
Bone mineral density measurements
Bone Mineral Density (BMD) measurements were performed time of screening for OLT 
(baseline) and at 6 and 12 months post-OLT. BMD was measured at the lumbar spine and 
femoral neck using dual energy X-ray absorptiometry (DXA- Hologic QDR 4500, Hologic 
inc. Waltham, MA, USA, equipped with reference values based on the National Health 
and Nutrition Examination Survey (NHANES III)). Absolute measurements of BMD in g/
cm2 as well as T-scores (matched to young adult reference populations at peak bone 
mass) and Z-scores (age- and sex-matched reference populations) were recorded. World 
Health Organization (WHO) criteria were used to define osteoporosis (T-score of -2,5 SD 
or less) and osteopenia (T-score between -1 SD and -2.5 SD).
Vertebral fracture assessment
Spinal radiographs were routinely performed at time of screening for OLT and at six 
and twelve months after OLT. Conventional antero-posterior and lateral radiographs 
of the thoracic spine and postero-anterior and lateral radiographs of the lumbar spine 
were performed by an experienced radiology technician following a standardized 
protocol, at a distance of 115 cm, with the film centralized on Th7 for the thoracic spine 
and on L3 for the lumbar spine. All plain radiographs of the thoracic and lumbar spine 
were blindly assessed for the prevalence and severity (grade) of vertebral fractures 
by two independent observers: an experienced musculoskeletal radiologist (H.M.K.) 
and an experienced bone and mineral disorders specialist (N.A.H.). Vertebral fractures 
were assessed using the Genant’s semi-quantitative method.(38) Using this method, a 
decrease in height of 20-25% is considered to be a “mild” grade 1 fracture, of 25-40% a 
“moderate” grade 2 fracture and of > 40% a “severe” grade 3 fracture. Uniform loss of 
vertebral height compared to adjacent vertebrae were additionally documented using 
the same grading scores. Radiographs were assessed in a random order, using random 
numbers generated by SPSS software (version 20). A unique number was assigned to 
each series of radiographs, which included anterior-posterior and lateral radiographs 
of the thoracic and lumbar spine. Radiographs were individually scored by the two 
independent observers and in case of discrepancy in scores, consensus was achieved by 
both observers reviewing the radiographs together.
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statistical analysis
For descriptive statistics, categorical variables were expressed as numbers and as 
percentages. Continuous variables were summarized using mean and standard 
deviation in case of an estimated normal distribution. Median and 5th and 95th 
percentiles were used otherwise. An incident fracture was defined as the occurrence of 
a new vertebral fracture or an increase in grade of a prevalent fracture between serial 
radiographs before and during the first year after OLT. An extension of a Generalized 
Linear Model, Generalized Estimation Equations (GEE), was used to account for repeated 
measurements.
At time of screening before OLT, the relationship between biochemical parameters, 
prevalent BMD, prevalent fractures and BTMs was calculated using a multivariate 
regression model, correcting for age and gender. The relationship between CTX and 
the BTMs of bone formation: P1NP, osteocalcin and BALP was analyzed using a linear 
regression model. Predictive value of changes in BTM’s for bone loss and for fracture 
incidence after OLT was analyzed also using a regression model. For the analysis of 
the influence of changes in BMT’s on fracture incidence, difference of BTMs between 
evaluation points was calculated and a regression model was subsequently used to 
analyze the predictive value of the change of BTM on fracture incidence. Calculations 
were performed using STATA/SE 12.0 software (Stata Corp LP, TX, USA).
results
a. baseline data at time of screening for olt
Demographic and clinical characteristics
P1NP measurements and stored sera were available at screening in 66 of the 73 patients 
who received an orthotopic liver transplantation in the study period 2008-2011. Of 
these 66 patients, 6 were excluded because they were receiving a second or third liver 
transplant, and 3 because they also received a renal transplant. A further 6 patients were 
excluded because of start of treatment with bisphosphonates before transplantation (n 
= 2) or during follow-up (n = 4). A total number of 51 patients were thus included in the 
study (Figure 1).
41 patients were male (80%) and median age was 59 years (range 23-66 years)
(Table 1). Most common primary liver disease was alcoholic liver disease (41%) followed 
by viral liver disease (26%) and cholestatic liver disease (4%). Only one patient died 
of an unknown cause 211 days after OLT. At time of screening, 4 patients (8%) were 





At time of screening, mean creatinine level was 88 ± 37 µmol/L. Mean 25(OH)D level was 
36 ± 27 nmol/L, with 82% of patients having levels of < 50 nmol/L and 43% of patients of 
< 25 nmol/L. Mean bilirubin level was 96 ± 212 mmol/L and mean MELD score was 13 ± 6.
Prevalent BMD
BMD was available at screening in 50 of the 51 patients. Lumbar spine (LS) data were not 
interpretable in two patients because of residual oral contrast material from abdominal 
CT-scans, required as part of the screening protocol for OLT, but chronologically 
performed by error before DXA. Mean LS BMD was 1.00 ± 0.16 g/cm2 and mean 
femoral neck (FN) was 0.80 ± 0.14 g/cm2 at the FN. The prevalence of osteoporosis and 
osteopenia was respectively 16 and 33 % at the LS and 4 and 44% at the FN.
OLT  
2008- 2011 
(n = 73) 
 
BTM measurement 
(n = 66) 
 
 
No BTM measurement 






Inclusion in the study 












Figure 1: Study flow-chart. OLT = orthotopic liver transplantation; BTM = bone turnover marker.
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Prevalent vertebral fractures
Conventional spinal radiographs were available in all patients. Vertebral fractures were 
prevalent at time of screening in 34 patients (67%), mostly grade 1 fractures.
Bone turnover markers
Mean P1NP level was 82 ± 47 ng/mL (normal < 59 ng/mL). Mean osteocalcin levels was 
9 ± 4 ug/L (mean Z-score -0.9 ± 1.6), mean BALP was 22 ± 9 U/L (mean Z-score 0.82 
Table 1 Demographic data at time of screening for liver transplantation.
Demographic data
Number of patients 51
Gender – number of male patients (%) 41 (80%)
Age at the time of OLT- Median (range), years 59 (23-66)
Death during follow-up – no of patients (%) 1 (2%)
Time of death after OLT – days 211
BMI – mean (SD), kg/m2 27 ± 6
Smoking – number of patients (%) 18 (38%)
Primary liver disease – number of patients (%)
Alcoholic 21 (41%)
Viral 13 (26%)
Combined alcoholic and viral 2 (4%)




Time between screening and OLT
- median (5th – 95th percentile), months 9 (1-33)
Rejection episodes – number of episodes (cumulative incidence, %)
6 months after OLT 2 (4%)
12 months after OLT 0 (4%)
Calcium – and vitamin D supplements – number of patients (%) 4 (8%)
Corticosteroids at the time of screening - number of patients (%) 1 (2%)
Immunosuppressive medication initiated at OLT
- number of patients (%)
Prednisone, tacrolimus 40 (78%)
Prednisone, tacrolimus and MMF 6 (12%)
Prednisone, cyclosporine and MMF 1 (2%)
Other 4 (8%)
OLT = orthotopic liver transplantation; BMI = body mass index; PSC = primary sclerosing cholangitis; 
PBC = primary biliary cirrhosis; MMF = mycofenolate mofetil. * including polycystic liver disease, cryp-
togenic cirrhosis, non-alcoholic steatosis hepatis, Caroli syndrome
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±1.7) and mean CTX level was 397 ± 326 pg/mL (mean Z-score 2.16 ± 3.5). There was a 
significant relationship between P1NP and CTX levels (p < 0.005), which was no longer 
significant after correcting for creatinine levels (p = 0.060).(Figure 2) There was no 
relationship between CTX and osteocalcin or BALP
Higher creatinine levels were associated with higher levels of P1NP (p<0.005), 
osteocalcin (p<0.005) and CTX (p < 0.005). There was no association between creatinine 
levels and BALP (p=0.984).
At time of screening, higher MELD scores were associated with higher P1NP levels 
(p < 0.005) and higher CTX levels (p <0.005). There was no association between MELD 
scores and BALP or osteocalcin levels (p = 0.070 and p = 0.260 respectively). There was 
no significant association between bilirubin levels or INR and any of the BTM’s before 
transplantation. Higher albumin levels were associated with lower CTX levels (p = 0.015).
Despite the low mean vitamin D levels at screening for OLT, there was no association 
between any BTM measured and 25(OH)D levels at this time point.
At screening, higher CTX levels but none of the other BTMs were predictive for lower 
BMD at the LS (p = 0.009) but not at the FN. None of the markers were predictive for 
prevalent vertebral fractures.
b. follow-up data in the first year after olt
Clinical parameters
Median time between screening and OLT was 9 months. After OLT, all patients were 
treated with prednisone, which was combined with tacrolimus in the majority of patients 
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Figure 2: Association between the bone resorption marker serum CTX and the bone formation marker 
serum P1NP. CTX= C-terminal telopeptide of type I collagen; P1NP = serum procollagen type 1 N-termi-
nal propeptide.
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prednisone in 2% of patients. 2 patients had rejection episodes during the first year after 
OLT. The cumulative incidence of rejection episodes, requiring high dose of corticosteroids, 
was 4% at 12 months after OLT. At twelve months after OLT, calcium and or vitamin D 
supplements were prescribed to 40% of patients compared to 8 % at time of screening.
Biochemical parameters
After OLT, bilirubin levels significantly decreased from 96 ± 212 mmol/L at time of 
screening to 18 ± 34 mmol/L at three months after OLT (p = 0.002) with complete 
normalization to < 17 mmol/L in 38 patients (76%) at this time point, remaining stable 
thereafter with a mean value of 23 ± 66 mmol/L at six months and 16 ± 19 mmol/L at 
twelve months after OLT. Creatinine levels remained mildly elevated after OLT with a 
value of 107 ± 35 µmol/L at twelve months after OLT. 25(OH)D levels increased within the 
first year after OLT, only reaching significance at twelve months after OLT with a mean 
value of 50 ± 27 nmol/L (p < 0.005).
Changes in BMD
There was no significant change in LS BMD at 6 or 12 months after OLT compared 
to baseline. Mean BMD at the LS was 1.01 ± 0.15 g/cm2 at twelve months after OLT 
compared to 1.00 ± 0.16 g/cm2 at baseline ( p = 0.236). There was however, a significant 
decrease in FN BMD after OLT from 0.79 ± 0.13 g/cm2 at time of screening to 0.75 ± 0.12 
g/cm2 at six months after OLT (p < 0.005) remaining stable thereafter with a mean BMD 
of 0.77±0.14 g/cm2 at twelve months after OLT ( p = 0.438 compared to values six months 
after OLT).
Incident fractures during the first year after OLT
Conventional spinal radiographs were available and evaluable in 49 of the 51 patients 
included in the study: in 45 at 6 months after OLT and in 37 patients at 12 months after OLT. 
Within the first year after OLT, new fractures were documented in 21 of the 49 patients (43%).
Bone turnover markers
Changes in BTMs were analysed in all patients included in the study. A separate analysis 
was also conducted in patients without incident vertebral fractures (n = 28) to avoid 
the possible effect of a recent fracture on the interpretation of BTMs. In the whole 
group, P1NP decreased after OLT from 82 ± 47 ng/mL at screening to 68 ± 38 ng/mL at 
three months and 77 ± 52 ng/mL at six months, both non-significantly, only reaching 
significance at twelve months after OLT with a level of 65 ± 50 ng/mL (p = 0.005) (Figure 
3). In patients without incident vertebral fractures during the first year after OLT, P1NP 
also decreased significantly (p = 0.003 at 12 months after OLT) whereas it did not in 
the 21 patients with incident vertebral fractures (p = 0.207). Changes in P1NP levels 
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in relation to changes in bilirubin, changes in creatinine and the presence or absence 
of a fracture within the first year after transplantation, highlighting the difficulty in 
interpreting this marker in liver transplant recipients, are shown in Figure 4.
Osteocalcin increased albeit not significantly in the whole group from 9 ug/L at 
screening to 12 ug/L at 3 months, 16 ug/L at 6 months and 15 ug/L at 12 months after OLT. 
However, in patients without new vertebral fractures, osteocalcin increased significantly 
from 9 ug/L at screening to 13.8 ug/L at six months (p = 0.010), remaining stable thereafter 
with a mean value of 14.5 ug/L at twelve months (p = 0.001 compared to screening).
There were no significant changes in mean BALP levels after OLT, although 17 out 
of 37 patients with measurements at both evaluation points (46%) demonstrated an 
increase in BALP at 6 months post-OLT. However, BALP decreased significantly from 23 
U/L to 11 U/L at three months (p= 0.004) in patients without incident vertebral fractures, 
remaining stable thereafter with a mean value of 14 U/L at twelve months after OLT (p= 
0.011 compared to screening).
The high CTX levels observed at screening remained unchanged during the first 
year after OLT. (Figure 3) In patients without vertebral fractures, CTX only showed an 
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Figure 3: Changes in bone turnover markers after OLT. BALP = bone specific alkaline phosphatase; P1NP 
= procollagen type 1 N-terminal propeptide; CTX = C-terminal telopeptide of type I collagen; * = signifi-
cant change compared to screening, p-value < 0.05.
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c. Predictive value of btms at screening for olt for bone loss and 
fracture incidence up to a year after transplantation
Higher CTX levels were associated with a decrease in LS (p = 0.008) as well as FN BMD 
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Figure 4: Highlight of factors affecting interpretation after transplantation. P1NP = procollagen type 1 
N-terminal propeptide. * = significant change compared to screening, p-value < 0.05.
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for bone loss in the first year after OLT (P1NP LS p = 0.472 and FN p = 0.064, BALP LS p = 
0.100 and FN p=0.321 , osteocalcin LS p = 0.278 and FN p = 0.308).
Higher CTX values were also predictive for increased fracture risk (p = 0.038 for 
absolute CTX values, p =0.014 for Z-scores after correction for age and gender). None 
of the other BTMs predicted incident fractures after OLT either considering absolute 
values (P1NP p = 0.373, BALP p = 0.429 and osteocalcin p = 0.993) or Z-scores (BALP p 
=0.215, osteocalcin p = 0.857). Absolute values of BTMs measured at three months after 
OLT were also not predictive for incident fractures (P1NP p = 0.927, osteocalcin p = 0.414, 
BALP p = 0.458, CTX p = 0.559) and neither were BTM Z-scores (CTX p= 0.823, BALP p = 
0.937, osteocalcin p = 0.161).
d. Predictive value of changes in btms for fracture risk within the 
first year post-olt
An increase of BALP levels between screening and 6 months after OLT was associated 
with an increased risk of fractures (p = 0.001). Changes in any of the other BTMs 
between screening and six months after OLT were not predictive for incident fractures a 
year after OLT (P1NP p = 0.798, osteocalcin p = 0.066, CTX p = 0.205).
discussion
Our data from this study demonstrate the limited value of the widely used bone 
turnover markers in the prediction of bone loss and of fracture risk before and after 
orthotopic liver transplantation. Although P1NP levels were increased and osteocalcin 
levels were decreased at screening before OLT, these markers as well as baseline bone 
alkaline phosphatase were neither predictive for prevalent BMD or prevalent vertebral 
fractures before transplantation, nor were they predictive for bone loss or increased 
fracture risk after transplantation. Only increased CTX levels at time of screening for OLT 
were predictive for bone loss and increased fracture risk after OLT. An increase in BALP at 
6 months after OLT was also predictive for increased fracture risk a year after OLT.
Bone turnover markers are biochemical products of bone remodelling, which reflect 
the metabolic activity of bone, and can be easily measured in serum or urine using semi-
automated techniques. The measurement of BTMs is non-invasive, free of radiation and 
easily incorporated into routine follow-up protocols. Serum and urine examinations 
are routinely used in the monitoring of patients with liver transplantation, so that 
measurements of bone turnover markers may be easily scheduled in these patients. The 
question which arises is whether measuring bone turnover markers would be of value 
in the management of the commonly encountered skeletal complications of end-stage 
liver disease, before and after liver transplantation. BTMs have been shown to predict 
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bone loss and fracture risk in postmenopausal women.(18;39) However, there are scarce 
data on the value of BTMs in patients with end-stage liver disease before and after liver 
transplantation and available data are conflicting, particularly after transplantation. 
There are a number of potential reasons for the difficult interpretation of BTMs after all 
solid organ transplantation including the effect of glucocorticoids on bone remodelling 
and the effect of calcineurin inhibitors possibly because of their potential nephrotoxic 
effect often associated with increases in PTH concentrations.
The Position Paper on bone markers issued by the IOF in 2011 recommends the use 
of P1NP as the preferred bone formation marker, as it reflects the synthesis of the 
most abundant protein of the organic bone matrix. P1NP is a peptide derived from the 
posttranslational cleavage of the type I pro-collagen molecule by specific protease 
enzymes during bone formation, which is released into the circulation where it can 
be easily and reliably measured. However, although most circulating P1NP is mainly 
derived from pro-collagen secreted by osteoblasts during the process of bone formation 
(39) and collagen type I constitutes more than 90% of the organic bone matrix. P1NP is 
not strictly speaking a bone-specific marker as it is also released in the circulation by 
fibroblasts in soft connective tissue, including hepatic connective tissue. P1NP is thus as 
much a serum marker of connective tissue metabolism as it is of bone metabolism. P1NP 
is cleared from the circulation by both renal and liver extraction so that impairment of 
either or both clearing mechanisms by liver and/or renal impairment may influence its 
serum levels. On the other hand, P1NP measurements are stable with minimal diurnal 
variation and no effect of food on circulating levels.
In our study, we could find no association between the high baseline P1NP values 
and either prevalent BMD or prevalent fractures before transplantation, or bone loss or 
increased fracture risk post-transplantation. In chronic liver disease, the marked increase 
in connective tissue synthesis and degradation of hepatic collagen type I (40;41), which 
does not reflect bone remodelling but rather liver fibrogenicity, has been previously 
demonstrated in animal models of liver fibrosis (42), in patients with progressive 
fibrosis of the liver due to primary biliary cirrhosis and in patients with alcoholic liver 
cirrhosis (31;43). In our study, we observed a significant decrease in P1NP levels after 
OLT, parallel with increases in osteocalcin levels, both closely related to improvement 
in hepatobiliary function as shown by significant post-OLT decreases in bilirubin 
levels(Figure 4). Intriguingly, we could not demonstrate a significant relationship 
between bilirubin levels and P1NP either at baseline or within the first year after 
transplantation, although both markers showed parallel decreases with time. A reason 
for this is likely to be that although bilirubin is a useful marker of liver function, it may 
not be a sufficient surrogate marker for all aspects of liver function.
Osteocalcin is a non-collagenous protein of the bone matrix, exclusively synthesized 
by the osteoblast during the process of bone formation, which should have potentially 
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been a more useful marker of bone turnover in patients with liver disease as it is a non-
collagen-derived marker and it is mainly cleared by the kidney so that it would not be 
affected by abnormal hepatic collagen production. (44;45) Our data confirm this premise 
as we could show no association between osteocalcin and MELD scores, bilirubin, INR 
or albumin. However, osteocalcin was disappointly also not predictive for either bone 
loss or increased fracture risk after OLT. A possible explanation for this may be that 
osteocalcin synthesis is vitamin K dependent (45), and that levels may decrease due to 
decreased synthesis of vitamin K in patients with end-stage liver failure. Osteocalcin is 
also rapidly degraded in serum to heterogeneous fragments and its circulating levels 
are influenced by circadian rhythms and by renal function, which is often disturbed in 
patients with end-stage liver disease before and after OLT.
Alkaline phosphatase (ALP) is secreted by osteoblasts in the extracellular fluid 
when newly formed osteoid undergoes maturation and mineralization. However, in 
healthy adults, only half of circulating ALP is derived from bone, the other half being 
predominantly of hepatic origin, with an even higher contribution of liver-derived ALP in 
patients with end-stage liver disease. The bone specific isoform BALP can be separately 
measured and has been shown to predict osteoporotic fractures in postmenopausal 
women.(46) In our study, we did observe that an increase in BALP 6 months after OLT 
was predictive of fracture risk within the first year after OLT. There was no association 
between BALP and creatinine levels or MELD scores suggesting that BALP may be less 
influenced by changes in liver or renal function after OLT.
The IOF recommends CTX as the reference marker for bone resorption.(39) CTX is a 
degradation product of type 1 collagen and consists of the C-terminal crosslinks of the 
collagen molecule, which are released into the circulation during bone resorption. CTX 
has been shown to be one of the most sensitive markers of bone resorption with a more 
consistent association with fracture risk than bone formation markers (46). However, 
CTX is a marker of bone resorption based on collagen degradation, which has also been 
found to be increased in patients with primary biliary cirrhosis just as P1NP is.(31) It is 
thus likely that in liver failure, measured levels of CTX would not exclusively reflect 
degradation of bone collagen, but also that of increased hepatic collagen synthesis 
and degradation. Higher MELD scores, reflecting severity of liver disease, were indeed 
associated with higher CTX levels which supports a relationship between hepatobiliary 
function and CTX.
Interestingly, however, high pre-transplantation levels of CTX were predictive not 
only of post-transplantation bone loss, but also of increased fracture risk. The better 
predictive value of a bone resorption marker over that of a bone formation marker 
for fracture risk is that bone formation lags behind bone resorption, needing some 3 
months or more to fill the newly formed resorption cavities, in the process of which, 
the unfilled resorbed areas would significantly weaken the microarchitecture of bone 
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resulting in a decrease in bone quality and a consequent increase in bone fragility, 
independently of the actual amount of bone lost. Our data are in keeping with this 
premise, showing an increased fracture risk associated with persistently increased levels 
of the bone resorption marker CTX and with increasing bone turnover as suggested by 
increasing bone alkaline phosphatase levels, despite the absence of significant bone loss 
at the lumbar spine as suggested by stable BMD values at this site in the first year after 
OLT.
Our study has strengths as well as limitations. A main strength of the study is that the 
cohort studied is representative of a liver transplantation cohort. A predefined protocol 
was applied with BMD measurements and conventional radiographs of the spine being 
routinely undertaken and thus available at screening and at regular intervals thereafter 
in the majority of patients. A further strength of our study is the long established 
practice of storage of sera in a Biobank in the Liver Transplantation Program, as a result 
of which stored serum samples could be analysed in case of missing data and further 
used for the measurement of P1NP, osteocalcin, BALP and CTX.
Our study has also a number of limitations. One of the limitations is the lack of a 
well-defined marker of liver function except for the validated laboratory MELD score. 
This score includes in addition to bilirubin and INR, creatinine and albumin as surrogate 
markers for the poorly prognostic hepatorenal syndrome. Whereas MELD scores are 
commonly used to evaluate severity of liver disease and thus of prognosis at the time of 
screening before OLT, these scores are not actually validated for the evaluation of liver 
function after OLT. A further limitation of our study is the relatively small number of 
patients included in the study, which may have precluded the detection of significant 
differences due to lack of power.
The fact that serum measured for CTX was not collected as recommended in the 
fasting state due to the retrospective nature of our study may also be perceived as a 
limitation in the interpretation of our results due to the known circadian rhythm of the 
marker and the influence of food intake on its circulating levels. However, it has been 
shown that non-fasting levels of CTX are about 20% lower than fasting ones, so that 
measured non-fasting levels would represent if anything an underestimate of the actual 
levels. It has also been previously shown that the afternoon level of CTX was more 
closely related to fracture risk than the morning sample.(47)
Although biochemical markers of bone turnover are widely available for use in the 
Clinic, their role in the prediction of bone loss and of fracture risk remains inconclusive 
and their value in the management of post-transplantation bone disease remains 
highly debatable. This is indeed the case in chronic liver disease, before and after 
liver transplantation, because of the many pitfalls encountered in the interpretation 
of these markers in the presence of disturbed connective tissue metabolism as 
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well as the confounding effect of corticosteroids and calcineurin inhibitors used for 
immunosuppression.
In conclusion, our data highlight the pitfalls in the interpretation of BTMs in chronic 
liver disease before and after liver transplantation. Based on our findings, we would 
recommend that caution should be advocated with the use of BTMs in the clinic in 
patients with chronic liver disease before and after liver transplantation until further 
evidence is obtained for the value of available or newer BTMs for therapeutic decision 
making in the management of skeletal complications in these patients.
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Introduction Bone loss and fractures are common after orthotopic liver transplantation 
(OLT). Data on the efficacy of bisphosphonates to decrease skeletal complications are 
not concordant and therapeutic strategies to decrease skeletal morbidity after OLT 
remain to be established.
Materials and methods A review was undertaken of published studies on the effect of 
bisphosphonates on bone loss and fracture risk in liver transplant recipients. Changes in 
bone mineral density (BMD) measurements routinely obtained before and 6 months and 
one and two years after OLT were analyzed in consecutive recipients of a successful OLT 
at the Leiden University Medical Centre between 2000 and 2011, who were treated with 
the bisphosphonate alendronate within the first year after OLT. Non bisphosphonate-
treated transplant recipients were used as controls. Conventional spinal radiographs 
available at time of screening for OLT and at six and twelve months post-OLT were 
assessed for vertebral fractures using the Genant’s semi-quantitative method.
Results Review of the published literature generated 16 studies, in all but 3 of which 
bisphosphonates were started around the time of OLT at various doses, frequency of 
administration and duration. Decreased fracture risk was the primary end point in only 
one study. A short-term beneficial effect of bisphosphonate treatment on BMD was 
observed in most studies. Data on long-term effect of treatment are conflicting.
Leiden case series: Data of 39 OLT recipients (mean age 49 yrs, 72% male) treated with 
oral alendronate within the first year after OLT (median 185 days, range 22-365) were 
compared to those of 104 controls (mean age 53 yrs, 68% male) transplanted within 
the same period and not receiving bisphosphonates. At baseline, BMD was lower 
in the bisphosphonate-treated group (p 0.005) at one or both sites measured with 
osteoporosis observed in 41% and osteopenia in 56% of patients compared to 39 and 11% 
respectively in the control group. Radiological vertebral fractures were equally prevalent 
in both groups (61% of patients in the treatment group and 55% in the control group). 
LS BMD increased equally in treated and non-treated patients. FN BMD remained stable 
in the treatment group, but decreased in the control group. There was no significant 
difference in changes in BMD at either site between treated and untreated patients or 
between patients in whom treatment was initiated between 3 and 6 months or more 
than 6 months after OLT.
Conclusion Our data suggest that although preventing further bone loss, 
bisphosphonate treatment not initiated shortly after OLT does not significantly 
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influence post-transplantation changes in BMD compared to controls. Whether 
bisphosphonate use is associated with a significant decrease in fracture risk remains to 
be established by long-term randomized controlled studies using these agents.
introduction
Vertebral fractures are prevalent in patients with end-stage liver disease awaiting 
orthotopic liver transplantation (OLT).(1) Accelerated bone loss is observed in the first 
six months after transplantation despite correction of the metabolic abnormalities 
associated with disturbed liver function, and fracture risk remains high despite 
post-OLT recovery of bone mineral density (BMD).(1-12) The initial rapid decline in BMD 
after OLT has been consistently shown to be followed by a recovery of bone mass to 
pre-transplant values one year after OLT.(1;4-7;9;10;13) However, we and others have 
demonstrated that this recovery in BMD is not associated with a corresponding decrease 
in the incidence of new fractures which have been documented in 25-34% of transplant 
recipients at one year after OLT.(1;8;10;12;14-17) A meta-analysis conducted in 2011 
provides evidence that treatment with bisphosphonates generally prevents or decreases 
bone loss and decrease fracture risk in patients with solid organ transplantation.(18) The 
rapid decline in bone mass observed within the first 6 months after OLT combined with 
the increased bone turnover demonstrated by the histomorphometric analysis of paired 
bone biopsies obtained at transplantation and 3-6 months after OLT as well as the 
prevention of this increased bone turnover by very early use of bisphosphonates provide 
the rationale for the use of bisphosphonates in OLT recipients to prevent or decrease the 
associated high fracture risk observed within the first year after OLT.(19;20) However, 
data on the potential beneficial effect of bisphosphonates to decrease or prevent bone 
loss and fracture risk after OLT remain scarce with available data obtained from 16 
studies with short follow-up duration or including a small number of patients, with a 
new fracture being the primary end-point in only one randomized controlled trial (RCT).
(19-34;34) A meta-analysis conducted in liver transplant recipients did demonstrate 
that bisphosphonates had a beneficial effect on bone loss but fracture risk could not be 
evaluated because of heterogeneity of available data.(35) Three studies have previously 
addressed the efficacy of the orally administered nitrogen-containing bisphosphonate 
alendronate to decrease or prevent bone loss and fracture risk within the first year after 
OLT.(31;34;36)
The aims of our study were to review published data on the effect of bisphosphonate 
treatment on bone loss and fracture risk after OLT, and to evaluate the effect of 
bisphosphonate treatment (oral alendronate administered weekly) initiated within the 




a. comprehensive review of the literature
Objective
To review available data on the effect of bisphosphonate treatment to decrease or 
prevent bone loss and fracture risk when administered to liver transplant recipients 
before, at or after OLT.
Design
Review of all RCT’s and controlled or open observational studies published until May 
2014 on the effect of a bisphosphonate of any type administered at any time around 
OLT, at any dose or schedule, and for any duration after OLT, on BMD and on fracture risk 
after OLT.
Data source 
Pubmed, Embase, reference lists of published papers.
Method
The comprehensive search strategy included the following terms: liver transplantation, 
ibandronate, bisphosphonates, alendronate, etidronic acid, zoledronic acid, risedronic 
acid, alendronate, bone mineral density, fractures.
The search was conducted in May 2014 through a search of two databases (Pubmed 
and Embase) and screening reference lists of published papers. All recovered abstracts 
were screened. All search generated published papers were carefully read to extract 
details of treatment and its efficacy.
b. case series from the leiden liver transplantation cohort study
Patients and methods
Patients
The electronic hospital records of all consecutive patients who underwent a first OLT at 
the Leiden University Medical Centre between January 1st 2000 and January 1st 2011 were 
screened for treatment with bisphosphonates initiated at any time within the first year 
after transplantation. Only patients with available BMD measurements before start 
of treatment and at one and two years after OLT were eligible for entry in the study. In 
our unit, treatment with bisphosphonates uniformly consisted of oral alendronate at 
a dose of 70 mg per week in addition to calcium- and vitamin D supplementation at a 
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combined fixed dose of 500 mg elemental calcium and 400 IU colecalciferol. There was 
no preplanned protocol for, or prerequisites or time for initiation of treatment with 
these agents after OLT, which was left at the discretion of the treating physician. The 
remaining consecutive patients who were transplanted within the same 10-year period 
and who also had BMD data available at one and two years after OLT, but who were 
never treated with bisphosphonates before or after OLT were used as controls. Patients 
in whom treatment with bisphosphonates was initiated before OLT were excluded from 
the study because of the lack of baseline data before or at start of treatment
Immunosuppressive regimens consisted of corticosteroids for at least 6 months in 
all patients, with a calcineurin inhibitor: tacrolimus or cyclosporine in the majority, 
and with mofetil mycophenolate (MMF) or sirolimus or everolimus as additional 
immunosuppressive agent in a few. International guidelines for immunosuppression 
were complied with in the case of newly transplanted patients, but established 
successful immunosuppressive regimen were seldom altered in individual transplant 
recipients. Basiliximab 20 mg was given in the anhepatic phase and on day 4. 
Corticosteroid schedules included methylprednisolone at a dose of 500 mg given during 
the OLT procedure, followed by oral prednisolone at a dose of 20 mg daily for one week, 
10 mg daily for 3 months, slowly tapering to complete discontinuation of corticosteroids 
between 3 and 6 months after OLT in all but a few patients who required maintenance 
doses of prednisolone of 2.5 – 10 mg/day. Treatment of rejection episodes consisted of 
methylprednisolone at a single dose of 1000 mg or – in severe cases- of three doses 
of 1000 mg, followed by oral prednisolone at a dose of 140 mg tapered by 20 mg a 
day until a dose of 20 mg daily was reached. The number of rejection episodes were 
recorded in individual patients.
Methods
Demographic and clinical data
Demographic and clinical data were obtained from individual patients’ electronic 
hospital records. Data on age, gender, smoking, height, weight, primary liver disease and 
date and cause of death were extracted from the records. Concomitant or later renal 
transplantation was documented. Data on immunosuppressive regimen, calcium and 
vitamin D supplements and date of initiation and discontinuation of alendronate were 
also recorded.
Laboratory investigations
Laboratory data were also obtained from electronic hospital records. Biochemical 
data collected included serum calcium, corrected for an albumin of 40 g/L, phosphate, 
creatinine, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25-OHD) 
concentrations, which were measured at screening for OLT and at various time points 
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thereafter in the two years after OLT. Bone turnover markers were not routinely 
measured in all patients so that because of the scarcity of available data these were 
not used in the analysis. Severity of liver disease was determined using the laboratory- 
Model for End-stage Liver Disease (MELD) scores (37) calculated on the basis of serum 
creatinine, bilirubin and INR measurements obtained at time of screening for OLT. The 
following accepted formula was used to calculate the scores:
MELD = 10 * (0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43
Bone mineral density measurements
BMD was measured at the lumbar spine and at the femoral neck using dual energy 
X-ray absorptiometry (DXA- Hologic QDR 4500, Hologic inc. Waltham, MA, USA, equipped 
with reference values based on the National Health and Nutrition Examination Survey 
(NHANES III)). Absolute measurements of BMD in g/cm2 as well as T-scores (matched 
to a young adult reference population at peak bone mass) and Z-scores (age- and 
sex-matched reference population) were recorded. World Health Organization (WHO) 
criteria were used to define osteoporosis (T-score of -2.5 SD or less) and osteopenia 
(T-score between -1 SD and -2.5 SD). BMD measurements were performed at time of 
screening for OLT (baseline) and at 6, 12 and 24 months after OLT.
Vertebral fracture assessment
Conventional spinal radiographs were performed as part of the standard protocol for 
evaluating skeletal complications at screening before OLT and at six and twelve months 
after OLT.
All radiographs of the thoracic and lumbar spine were blindly assessed for the 
prevalence of vertebral fractures by two independent observers, using the Genant’s 
semi-quantitative method.(38)
Laboratory, BMD and fracture data collected at time of screening for OLT were 
considered to be baseline data.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre.
Statistical analysis
For descriptive statistics, categorical variables were expressed as numbers and as 
percentages. Continuous variables were summarized using mean and standard 
deviation in case of normal distribution of data. Median and 5th and 95th percentiles 
were used otherwise.
Patients in whom treatment was initiated in the first year after OLT were analyzed 
on an intention to treat basis. BMD changes were compared with those of patients not 
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receiving treatment with bisphosphonates, using an extension of a Generalized Linear 
Model, Generalized Estimation Equations (GEE) with correction for BMD, change in BMD 
compared to screening, fractures prevalent before OLT and incident fractures after OLT, 
age, gender and bilirubin levels (reflecting hepatobiliary function).
Prevalence of fractures was calculated by dividing the number of patients with 
at least one vertebral fracture by the total number of patients with available spinal 
radiographs. The incidence of fractures was defined as the occurrence of a new vertebral 
fracture or an increase in grade of a prevalent fracture between serial radiographs 
before and in the first year after OLT. A GEE model was used to evaluate the influence of 
change of BMD on fracture risk, corrected for age and sex and accounting for repeated 
measurements. P-values < 0.05 were considered significant.
Calculations were performed using STATA/SE 12.0 software (Stata Corp LP, TX, USA).
results
a. comprehensive review of the literature
Review of the literature generated sixteen studies, including nine RCT’s and seven 
observational studies, and a total of 729 patients treated with bisphosphonates orally or 
intravenously after OLT. Details of the studies elicited by the literature search are shown 
in Table 1.
1. Details of bisphosphonate treatment
Bisphosphonates used were largely nitrogen-containing bisphosphonates including 
oral alendronate and risedronate and intravenous zoledronate, ibandronate and 
pamidronate. Two early studies reported results with the use of the first generation 
bisphosphonate etidronate.(29;30) Mode of administration was intravenous in most 
studies (total number of patients treated 499)(19-23;25-30;32;33) and oral in 4 studies 
(total number of patients treated 235)(24;26;31;34). Time of initiation of treatment 
was before OLT in 3 studies (total number of patients treated 66 patients with exact 
number of patients treated not mentioned in one study)(28;29;31), at or shortly after 
OLT in 10 studies (total number of patients treated 488)(19-22;24-26;32-34;39), and 1-2 
years after OLT in 3 studies (total number of patients treated 82)(23;27;30). Duration 
of treatment was one year in 7 studies (total number of patients treated 303 patients)
(19;21;22;25;26;30;32;34) or 2-3 years in 5 studies (total number of patients treated 251)
(23;24;27;31;34). Details of duration of other treatments are shown in Table 1. Follow-up 
duration was 9 months in one study (total number of patients treated 13)(28), one 
year in 9 studies (total number of patients treated 413)(19-22;24;26;29;30;32-34) 
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BMD was sequentially evaluated in 15 studies (total number of patients treated 693)
(19-27;29-34;39), and incidence of new fractures was reported in 13 studies (total 
number of patients treated 608)(19-21;23-29;31;33;34;39), in 2 studies on the basis 
of clinical fractures (25;28), and in 10 studies the basis of sequential X-rays.(19;21;23-
27;29;31;33;34;39) Only one study had incidence of new fractures as a primary end-
point(19;21).
2. Effect of bisphosphonate treatment on bone turnover
Most studies have evaluated the effect of bisphosphonates on bone turnover using 
changes in bone turnover markers. The bone turnover marker used as bone formation 
marker was osteocalcin in most studies, bone alkaline phosphatase in some, and in 
later years procollagen type 1 N-terminal propeptide (P1NP). Bone resorption markers 
used were mostly urinary deoxypyridinoline and in later years serum beta crosslaps 
(CTX). A decrease in bone turnover markers is reported after the initiation of treatment 
with bisphosphonates in the majority of studies (21-27;29;32;34;39). This decrease in 
bone turnover has also been histologically confirmed by histomorphometric analysis 
of paired bone biopsies obtained at start of bisphosphonate treatment shortly after 
transplantation , and 3-6 months after transplantation.(19;20)
3. Effect of bisphosphonate treatment on bone loss
Most studies show a short-term beneficial effect of treatment initiated at or shortly 
after OLT on BMD.(22;24-26;31-34;39) The conclusion reached by authors of a meta-
analysis published in 2010 was that bisphosphonate treatment administered during the 
critical first months after OLT appeared to reduce accelerated bone loss and to improve 
lumbar spine (LS) BMD.(35) Data on long-term effect of treatment with bisphosphonates 
administered at or shortly after OLT on BMD are scarce and conflicting. Treatment with 
bisphosphonates in the form of pamidronate administered as a single infusion before 
OLT did not prevent post-transplantation bone loss in the long-term.(29) Three studies 
showed a persistent beneficial effect on BMD up to 27 months after OLT (25;31;34) 
but this was not confirmed in a fourth study.(21) Three studies in which treatment 
was initiated longer than a year after OLT show no bone loss after start of treatment.
(23;27;30)
4. Effect of bisphosphonate treatment on fracture risk
Data on both short-term and long-term effect of bisphosphonate treatment on 
fracture risk are conflicting, with studies showing a decreased fracture incidence in 
treated patients with oral as well as intravenous bisphosphonates, when treatment is 
initiated before, at or shortly after transplantation, or 1-2 years after OLT with a range 
of treatment duration of 9-24 months (23;25;26;28;31;34;39), whereas other studies do 
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not show any beneficial effect on fracture risk.(21;24;27;29;33) Of note is that 2 studies 
report only clinical fractures (25;28) whereas 10 studies radiographic fractures (19;21;23-
27;29;31;33;34;39) and 4 studies report only on BMD changes (20;22;30;32). In the only 
published meta-analysis, the effect of bisphosphonate treatment on fracture risk could 
not be analysed because of the heterogeneity of the available data.(35)
Conclusion
A comprehensive review of published literature up to May 2014 suggests that 
bisphosphonate treatment when administered at or shortly after OLT is able to decrease 
the rapid early post-transplantation bone loss and to improve bone mass in the short 
term, irrespective of type of bisphosphonate used or duration of treatment. Data on 
long-term effects of these agents particularly when started 6 months or longer after OLT 
on BMD and fracture risk are conflicting.
b. leiden case series
Baseline data
Demographic characteristics
223 patients with end-stage liver disease received an orthotopic liver transplant at 
the Leiden University Medical Centre between 2000 and 2011 and were eligible for 
the study (Figure 1). Twenty-one patients were excluded from analysis because of 
use of bisphosphonates at time of screening for OLT. Bisphosphonate treatment was 
initiated within the first year after OLT (median 185 days after OLT, range 22-365 days) 
in 44 patients, of whom 39 patients had available BMD measurements before start of 
treatment and at one and 2 years after OLT. Bisphosphonate treatment was initiated 
within the first 6 months after OLT (median 100 days after OLT, range 22-179) in 15 
out of these 39 patients. The control group consisted of 104 patients not treated with 
bisphosphonates in whom BMD measurements were also available at the same time 
points. Demographic details of bisphosphonate treated and untreated OLT recipients are 
shown in Table 2. 72% and 68% of patients were men in the treatment and control group 
respectively, with a respective median age of 49 and 53 years. Most common primary 
liver disease was viral disease in both groups (33 and 29% in the treatment group and 
control group respectively), followed by alcohol liver disease (23% and 25% respectively) 
and cholestatic liver disease (15 and 14% respectively). Median time between screening 
and transplantation was 9 and 10 months in the treatment and control group 
respectively.
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Laboratory data
Vitamin D levels were significantly lower in bisphosphonate treated patients before 
OLT, with a mean vitamin D level of 24 ± 17 nmol/L compared to a mean level of 35 ± 24 
nmol/L in the control group (normal 50-250 nmol/L, p = 0.043). In the treatment group, 
88% of patients had vitamin D levels < 50 nmol/L, and 53% < 25 nmol/L, compared to 
the control group, in which 80% of patients had vitamin D levels below 50 nmol/L, 
and 38% below 25 nmol/L. There was no significant difference in any other laboratory 
parameter measured at time of screening for OLT between bisphosphonate treated and 
non-treated OLT recipients, including mean serum creatinine, bilirubin and MELD scores, 
reflecting severity of liver disease.
BMD data
BMD data were available as per inclusion criterion in all patients studied but LS 
data were not interpretable in a number of patients (n= 10) because of residual oral 
contrast material from abdominal CT-scans, required as part of the screening protocol 
for OLT, but chronologically performed by error before DXA in these patients. BMD 
measurements were significantly lower in the bisphosphonate treated group, with a 
mean LS BMD of 0.85 ± 0.15 g/cm2 compared to 1.00 ± 0.17 g/cm2 in the non-treated 
control group (p < 0.005). Femoral neck (FN) BMD was 0.71 ± 0.12 g/cm2 in the 
bisphosphonate treated group compared to 0.85 ± 0.13 g/cm2 in the non-treated group 
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Figure 1: Flow-chart of the study. OLT = orthotopic liver transplantation; BMD = bone mineral density 




Table 2: Demographic data at time of screening and after liver transplantation
Demographic data Treatment 
group
Control group P-value
Number of patients 39 104
Gender – number of male patients (%) 28 (72%) 71 (68%) 0.684
Age at the time of OLT- Median (range), years 49 (18-68) 53 (19-67) 0.488
Death during follow-up – no of patients (%) 0 0
BMI – mean (SD), kg/m2 25 ± 4 26 ± 5 0.105
Smoking – number of patients (%) 6 (17%) 38 (38%) 0.026†
Primary liver disease – number of patients (%)
Viral 13 (33%) 30 (29%) 0.133
Alcoholic 9 (23%) 26 (25%) 0.002†
Cholestatic (PSC / PBC/ overlap syndrome) 6 (15%) 15 (14%) 0.058
Auto-immune hepatitis 3 (8%) 4 (4%) 0.706
Malignancy 2 (5%) 5 (5%) 0.273
Metabolic 0 (0%) 3 (3%) -
Other* 6 (15%) 21 (20%) 0.007†
Previous or concomitant renal transplantation
- number of patients (%) 2 (5%) 3 (3%) 0.502 
Time between screening and OLT
- median (5th – 95th percentile), months 9 (1-19) 10 (1-25) 0.371 
Second OLT
- number of patients (%) 4 (10%) 16 (15%) 0.445 
- time to second OLT – median (5th – 95th percentile), months 6 (1-11) 4 (0-23)  
Rejection episodes – number of episodes (cumulative 
incidence, %)
6 months after OLT 14 (37%) 10 (10%) < 0.005†
12 months after OLT 0 (0%) 1 (11%) 0.498#
24 months after OLT 2 (45%) 5 (17%) 0.773#
Calcium – and/or vitamin D supplements at time of 
screening– - number of patients (%)
5 (13%) 11 (11%) 0.918
Corticosteroids at time of screening - number of patients (%) 2 (5%) 4 (4%) 0.760
Immunosuppressive medication initiated at OLT
- number of patients (%)
Prednisolone, tacrolimus 15 (39%) 42 (40%) 0.834
Prednisolone, cyclosporine 10 (26%) 26 (25%) 0.937
Prednisolone, cyclosporine and MMF 5 (13%) 12 (12%) 0.833
Prednisolone, tacrolimus and MMF 3 (8%) 11 (11%) 0.607
Other 6 (15%) 13 (13%) -
OLT = orthotopic liver transplantation; BMI = body mass index; PSC = primary sclerosing cholangitis; 
PBC = primary biliary cirrhosis; LS = lumbar spine; FN = femoral neck; MMF = mycofenolate mofetil. 
* including polycystic liver disease, Budd Chiari, portal vein thrombosis, acute fatty liver of pregnancy, 
cryptogenic cirrhosis, cystic fibrosis, Rendu Osler Weber syndrome; † = p-value < 0.05; # = p-value con-
cerning incident rejection episodes
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(p < 0.005). Mean LS and FN T-scores were respectively -1.98 ± 1.28 and -1.78 ± 1.12 in the 
bisphosphonate treated group and -0.70 ± 1.23 (p<0.005) and -0.63 ± 1.08 (p<0.005) 
in the control group. The prevalence of LS osteoporosis was higher in the treatment 
group than in the control group (35 vs 8%, OR 5.6, 95%CI 1.6-15.9, p =0.001) whereas the 
prevalence of osteoporosis at the FN did not differ between groups (19 and 8%, OR 2.9, 
95%CI 0.89-9.40, p =0.078). Osteopenia was also more prevalent in treated patients, 
with a prevalence of 52% at the LS compared to 31% in untreated patients ( OR 2.3, 95%CI 
1.0-5.4, p = 0.050), and a prevalence of 59% at the FN compared to 26% in untreated 
patients (OR 4.3, 95% CI 1.8-10.0, p = 0.001).
Prevalent vertebral fractures at screening for OLT
Conventional spinal radiographs were available and evaluable in 33 of 39 patients in 
the bisphosphonate treated group and in 92 of 104 patients in the non-treated control 
group at time of screening for OLT. Vertebral fractures were prevalent in 20 patients in 
the bisphosphonate treated group (61%) and in 51 patients in the control group (55%) 
with no significant difference between groups (p = 0.607). Vertebral fractures were 
thus equally prevalent in treated and untreated patients at screening for OLT despite 
significantly lower BMD measurements both at LS and FN in the bisphosphonate treated 
group.
Follow-up data after transplantation
Clinical course
Immunosuppression included prednisolone in all patients, with the majority also 
receiving tacrolimus (39% in the treatment group and 40% control group) or tacrolimus 
and MMF (8% and 11%). Cyclosporine or cyclosporine and MMF were given to 26% and 
15% of patients in the treatment group and to 25% and 12% of patients in the control 
group. Rejection episodes occurred mainly in the first year after OLT, with a significantly 
higher cumulative incidence of rejection episodes in bisphosphonate treated patients 
(37% versus 10% in the first six months after OLT), consequently reflecting significantly 
higher cumulative doses of corticosteroids in bisphosphonate treated than in 
non-treated patients (p = 0.002). All patients in the treatment group were receiving 
bisphosphonate treatment at 12 months after OLT. At the end of follow-up at 24 months 
after OLT, 34 out of the 39 patients (87%) in the treatment group were still using 
alendronate. Reasons for discontinuation of treatment were not clearly documented.
Laboratory data
There was a comparable significant improvement in bilirubin levels during the first year 
after OLT reflecting improvement in hepatobiliary function with mean bilirubin levels 
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significantly decreasing from 70 ± 60 mmol/L to 30 ± 66 mmol/L at six months after 
OLT ( p = 0.038) in the bisphosphonate treated group and from 88 ± 174 mmol/L to 15 ± 
11 mmol/L (p <0.005) in the control group, remaining stable thereafter in both groups. 
There was no difference in mean bilirubin levels between groups at screening for OLT, or 
thereafter at any time point measured. There was no significant difference in changes in 
bilirubin levels between groups ( p =0.928).
Changes in renal function were also comparable between groups (p =0.337). Serum 
creatinine levels increased significantly in the control group with a mean level of 107 ± 
44 µmol/L at 3 months after OLT (p =0.003) but remained stable thereafter. There was 
also an increase in creatinine levels albeit not significant in the bisphosphonate treated 
group, reaching levels of 97 ± 31 µmol/L at 3 months, 102 ± 32 µmol/L at 6 months and 
107 ± 32 µmol/L at 12 months after OLT (p = 0.179). There was no significant difference in 
serum creatinine concentrations between groups at any time point measured.
Vitamin D levels increased significantly after OLT in both groups, reaching significance 
at three months after OLT in the bisphosphonate treated group (p =0.020), with a mean 
level of 36 ± 24 nmol/L increasing to a mean level of 58 ± 25 nmol/L at 12 months after 
OLT (p <0.005 compared to 3 months after OLT) and remaining stable thereafter with 
levels of 60 ± 29 nmol/L at 24 months after OLT (p = 0.573 compared to 12 months after 
OLT). In the control group, vitamin D levels increased significantly at 12 months after OLT 
(p <0.005) with a mean value of 43 ± 24 nmol/L, and increasing further until 24 months 
after OLT with a mean value of 63± 36 nmol/L (p = 0.001 compared to 12 months after 
OLT). There was no significant difference in changes in vitamin D levels between groups 
(p = 0.870).
Sequential changes in BMD
Changes in BMD after OLT are shown in Figure 2 and 3. LS BMD decreased in all 
patients in the first six months after OLT, albeit significant only in the patients who 
subsequently did not receive treatment with bisphosphonates (p = 0.009), with no 
further decrease between 6 and 12 months after OLT. LS BMD increased significantly 
thereafter in both the bisphosphonate-treated and control groups, with values 
reaching pre-transplantation values in the control group (p= 0.382) and exceeding 
pre-transplant levels after OLT in the bisphosphonate treated group (p = 0.016) at 24 
months after OLT. Changes in BMD at the LS between 12 and 24 months after OLT did 
not differ significantly between the treatment and control groups (p =0.574). There was 
no difference in changes in BMD over the first 2 years of treatment between patients 
in whom treatment was initiated within the first six months after OLT compared to 
patients in whom treatment was initiated between six and twelve months after OLT 
(p=0.282).(Figure 3) There was also no difference in changes in BMD between the group 
111
Bisphosphonates in the prevention of bone loss after OLT
5
of patients in whom treatment with bisphosphonates was initiated within the first 6 
months after OLT and the untreated control group (p = 0.613).
FN BMD decreased significantly between screening and six months after OLT in 
both bisphosphonate-treated and untreated patients (p < 0.005)(Figure 2). In the 
bisphosphonate treated group, FN BMD stabilized after start of treatment (mean 167 
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Figure 2: Changes of BMD at the LS (upper panel) and FN (middle panel) and incidence of vertebral 
fractures (lower panel). P-values concerning increase of BMD between 12 and 24 months after OLT in 
bisphosphonate treated patients and untreated controls. BMD = bone mineral density; LS = lumbar 
spine; FN = femoral neck; * = significantly lower when compared to screening (p < 0.05); NS = not sig-
nificant. # = p-value concerning difference in incidence of new vertebral fractures between groups.
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with levels being significantly lower at 24 months than at 6 months after OLT (12 
months: p = 0.091; 24 months: p=0.024). In the treatment group, changes in FN BMD 
did not differ whether treatment was initiated within the first 6 months after OLT or 
between 6 and 12 months after transplantation (at 12 months p =0.955)(Figure 3). There 
was no significant difference in changes in BMD between the treated and control group 
between 12 and 24 months after OLT (p = 0.545), also when comparing the control group 
with that of patients in whom bisphosphonate treatment was initiated within the first 
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Figure 3: Percentage changes in BMD at the LS (upper panel) and FN (lower panel) in bisphosphonate 
treated patients in whom treatment was initiated within the first six months after OLT (n=15) or be-
tween six and twelve months after OLT (n = 24). OLT = orthotopic liver transplantation; BMD= bone 
mineral density; LS lumbar spine; FN = femoral neck; p - value reflecting difference in changes of BMD 
between patients in whom treatment was initiated before or after 6 months after OLT.
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Incident vertebral fractures during the first year after transplantation
Within the first year after transplantation, the incidence of fractures was significantly 
higher at 54% in the bisphosphonate treated group compared to 32% in the non-treated 
control group (p =0.010). At 12 months after OLT, the prevalence of fractures was 84% 
in the treatment group after an overall median time of initiation of treatment of 180 
days (range 343-0), and 70% in the control group (p =0.070)(Figure 2). Data on vertebral 
fractures were not available beyond the first year after OLT.
discussion
Our findings from this retrospective analysis of a single centre case series of OLT 
recipients treated with bisphosphonates indicate that treatment with bisphosphonates 
initiated within the first year after liver transplantation with a median time of 185 days 
after OLT and given for a median time of 17 months (range 4-23) does prevent bone loss 
after start of treatment although there was no significant difference in BMD at one and 
two years after OLT between treated and untreated patients.
Data on the protective effect of bisphosphonates on post-transplantation bone loss 
are scarce in liver transplant recipients, with studies conducted in small numbers of 
patients, treatment initiated either before, at or shorty after OLT or more than a year 
or later after transplantation.(22;23;25-29;34;39) Our study addresses the effect of 
bisphosphonate treatment initiated within the first year after OLT, not directly after 
transplantation, but after a median time of 185 days after OLT. Whereas treatment 
initiated within the first six months after OLT did decrease to some extent the 
accelerated bone loss characteristic of that period, it appears that it was not started 
soon enough after liver transplantation to prevent it all together. Notwithstanding, our 
findings do show an increase in LS BMD and a stabilization of FN BMD after initiation 
of bisphosphonate treatment, regardless of when treatment was initiated after OLT. 
Intriguingly, BMD changes were not significantly different between bisphosphonate 
treated and control patients at one and two years after transplantation. We and others 
have previously shown the spontaneous recovery of BMD to pre-transplant levels in liver 
transplant recipients not receiving bone-modifying treatment.(1;2;4;6;8;10;13;15;16;40) 
This recovery in BMD is believed to be at least partly due to the improvement of gonadal 
function and of vitamin D status as a result of restoration of hepatobiliary function 
as well as a result of the tapering and rapid discontinuation of corticosteroids within 
the first few months after transplantation. We have also shown, however, that this 
spontaneous recovery in BMD is not associated with a parallel decrease in fracture risk 
(1), suggesting that bone loss may not be the sole determinant of increased fracture risk, 
and that altered bone quality may persist and be a significant contributor to fracture 
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risk after liver transplantation. In our study, the incidence of new vertebral fractures was 
higher at one year after transplantation in the bisphosphonate treated group, which had 
also a higher prevalence of osteoporosis and fracture before OLT, with the caveat that at 
the end of the first year after OLT, only few patients had been treated long enough with 
bisphosphonates, and more rejection episodes had occurred within the first six months 
after OLT in treated patients than in non-treated controls, resulting in higher cumulative 
doses of corticosteroids thereby predisposing to more severe bone loss.
Most studies show a beneficial effect of bisphosphonate treatment on BMD when 
treatment is initiated at or very shortly after transplantation.(19;22;25;26;34;39) 
This is in keeping with the beneficial effect of bisphosphonates on the prevention of 
glucocorticoid-induced bone loss, which is associated with a decrease in fracture risk 
when these agents are initiated shortly after start of glucocorticoids.(41;42) However, 
a single peri-operative pamidronate infusion (within 3 months of OLT), or treatment 
administered only before OLT failed to prevent post-transplantation bone loss (20;29), 
which suggests that longer treatment may be necessary to achieve bone protection, 
particularly if high dose prednisolone is used as part of the immunosuppressive regimen 
in the first months after transplantation when rejection episodes are the most frequent. 
Only three studies, including one RCT, have previously evaluated the effect of the oral 
bisphosphonate alendronate in liver transplant recipients, showing an increase in BMD 
during the first year after OLT.(26;31;39) Data on the effect of treatment with other 
bisphosphonates are heterogeneous and results are conflicting.(19-30;32-34) Our data 
are in keeping with a study using oral risedronate treatment, which showed a temporary 
beneficial effect of treatment at 6 months on LS BMD but not on FN BMD and no effect 
at either site at 12 months after transplantation.(24) A number of studies have reported 
beneficial effects of intravenous zoledronate or ibandronate on BMD.(19;22;23;25-27) 
Only one study compared an oral and intravenous bisphosphonate (alendronate and 
zoledronate respectively) (26), showing a similar increase in LS BMD and stabilization of 
FN BMD with the use of either agent. In our study, BMD changes were not different in 
patients in whom treatment with alendronate was initiated during the first 6 months 
after OLT compared to those in whom treatment was started 6-12 months after OLT. 
However, in the majority of the patients in whom treatment was initiated within the 
first 6 months after OLT, it was started at least 3 months post-transplantation and 
therefore after the early and most vulnerable postoperative period when the highest 
corticosteroid dosages are likely to have been administered.
Our study has a number of strengths and limitations. Its main strength lies in 
the availability of sequential BMD measurements and serial conventional spinal 
radiographs in the most vulnerable first year after transplantation, and in the blinded 
semi-quantitative assessment of all spinal radiographs for vertebral fractures by two 
experienced independent observers. A further strength of the study is the availability of 
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data in a relatively large and representative group of patients not receiving treatment 
with bisphosphonates, which was used as control group, and which was largely 
comparable to the treatment group in every respect except for an expected lower BMD 
in the bisphosphonate-treated group, which was corrected for in the final analysis of 
data.
Our study has also a number of limitations. There was no pre-defined protocol for 
bisphosphonate therapy. The decision to treat and when to start treatment was left 
to the clinical judgment of the treating physician which may have provided some 
degree of bias. Even though treatment was not randomly allocated and patients 
with the lowest BMD and the more prevalent fractures received treatment, we were 
able to compare treated and untreated patients by correction for BMD as well as 
for other parameters. Another limitation of our study is the relatively small sample 
size of bisphosphonate treated patients, although comparable to that of previously 
published studies. Because of the small number of patients in whom treatment with a 
bisphosphonate was initiated in referring hospitals before OLT, the lack of data at start 
of treatment in these patients, and the variable duration of treatment before OLT, we 
decided to exclude these patients from analysis and were thus unable to assess the 
effect of starting treatment before OLT on BMD and fracture risk after transplantation. 
Another limitation of our study is the lack of data on fracture incidence beyond the first 
year after transplantation, because of which we were unable to evaluate the long-term 
effect of bisphosphonate treatment on fracture risk. Non-vertebral fractures were 
poorly documented so that we could also not examine any potential beneficial effect of 
bisphosphonates on their occurrence.
In conclusion, our data suggest that the incidence of vertebral fractures increases 
in the first year after transplantation and that treatment with bisphosphonates 
initiated 3 months or later but not immediately after transplantation may be too late to 
prevent or decrease the crucial and rapid bone loss characteristic of the early post-OLT 
period and its associated increased long-term fracture risk despite recovery of BMD. 
Whether this increased fracture risk may be modulated by the earlier and longer use of 
bisphosphonates after OLT to decrease or prevent skeletal morbidity after OLT remains 
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In this Thesis, we establish that skeletal complications are common after liver 
transplantation. Although this is predominantly in the form of osteopenia and mild 
grade vertebral fractures, it has nonetheless been clearly shown that both osteopenia 
and grade 1 fractures are also associated with increased fracture risk. The morbidity 
and the mortality associated with fractures dictates that all liver transplant recipients 
should be evaluated for these complications in addition to evaluating and correcting 
any vitamin D deficiency.
In Chapter 1, we review the important role of the liver in the tightly regulated, 
well-balanced process of bone remodelling. Through its metabolic and excretory 
function, the liver plays an important role in the absorption of the lipid-soluble vitamins 
A, E, D and K, the last two important in bone metabolism, and for the metabolism of 
vitamin D, IGF-1 and gonadal hormones also important for bone remodelling. In liver 
diseases, factors other than decreased liver function may influence bone turnover 
such as the underlying primary liver disease if due to inflammation (as seen in viral 
hepatitis and sclerosing cholangitis associated with inflammatory bowel diseases) or 
direct toxicity to bone cells (alcohol abuse in alcoholic liver disease or iron overload 
in hereditary haemochromatosis or bile salts in cholestatic liver disease). In patients 
awaiting liver transplantation, end-stage liver disease is often associated with a 
decrease in bone mass and an increase in fracture risk likely to be due to a decrease in 
bone quality, as not always associated with actual bone loss. After liver transplantation, 
significant bone loss still occurs despite recovery of liver function due to several factors 
predominantly including the high dose of corticosteroids used for immunosuppression 
and in the treatment of rejection episodes and the use of calcineurin inhibitors for 
immunosuppression with associated risk of renal impairment. Within the first year after 
OLT, fracture incidence is very high, with fractures occurring in 25-35% of transplanted 
patients within the first year after OLT.
In Chapter 2, we evaluated the prevalence of low bone mass and of vertebral fractures. 
We found a high prevalence of skeletal pathology in the form of mostly osteopenia 
and vertebral fractures, predominantly grade 1 fractures. We did take these fractures 
in consideration because these mild vertebral fractures have recently been shown to 
be clinically relevant as also predictive of increased future fracture risk. No association 
could be found between bone mineral density (BMD) and prevalent fractures, with a 
large number of patients having prevalent fractures despite normal or mildly decreased 
BMD. The independence of fracture risk from bone mineral density measurements 
suggest that decreased bone quality rather than bone quantity may play an important 
role in the increased fracture risk observed in these patients.
In Chapter 3, we studied the changes in bone mass after liver transplantation. We 
demonstrated that after the rapid bone loss observed within the first six months 
after transplantation, bone mass stabilizes at the femoral neck and improves at the 
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lumbar spine with spontaneous recovery to pre-transplant values at two years after 
transplantation. Nevertheless, new vertebral fractures occur in a third of transplanted 
patients within the first year after transplantation. There was no association between 
BMD and prevalent fractures at time of screening and fracture risk after liver 
transplantation. Of all potential risk factors, only male gender and higher age were 
associated with increased risk of fractures after transplantation but other factors 
including vitamin D deficiency and severity of liver disease were not.
It has been proven difficult to identify factors associated with increased fracture 
risk in liver transplant recipients. The association between clinical parameters such 
as primary liver pathology or severity of liver disease, and of bone mineral density 
(BMD) and fracture risk has thus been shown to be inconsistent and generally poor. 
Biochemical markers of bone turnover are widely available for use in the Clinic, although 
their role in the prediction of bone loss and of fracture risk remains inconclusive and 
their value in the management of post-transplantation bone disease remains highly 
debatable. In the case of chronic liver disease, before and after liver transplantation, 
this is largely due to the many pitfalls in the interpretation of the measurements in the 
presence of abnormal liver connective tissue metabolism resulting in increased extra-
skeletal collagen type I synthesis and degradation as well as because of post - solid 
organ transplantation confounding factors such as use of corticosteroids and calcineurin 
inhibitors. In Chapter 4 we report that although procollagen type 1 N-terminal 
propeptide (P1NP)  levels were increased and osteocalcin levels were decreased at 
screening before OLT, these markers as well as baseline bone alkaline phosphatase 
were neither predictive for prevalent BMD or prevalent vertebral fractures before 
transplantation, nor were they predictive for bone loss or increased fracture risk after 
transplantation. High C-terminal telopeptide (CTX) levels before  liver transplantation 
and an increase in bone-alkaline phosphatase (BALP) after liver transplantation probably 
reflect best the risk of bone loss and fracture in patients with end-stage liver disease 
in the first year after OLT. However, because of the many pitfalls in the interpretation 
of the most commonly used collagen-derived bone turnover markers in patients with 
liver disease, caution is strongly advocated with their use in the clinic in therapeutic 
decision making in the management of skeletal complications before and after liver 
transplantation.
In the previous Chapters we have shown that skeletal pathology is highly prevalent 
in liver transplant recipients. However, it is unclear how these patients should be 
treated in order to prevent further bone loss and decrease or prevent further fractures 
after transplantation. In Chapter 5, we conducted a comprehensive review of the 
literature on the efficacy of bisphosphonate treatment in liver transplant recipients, 
which showed that treatment initiated shortly after OLT generally decreases bone loss 




treatment on BMD are conflicting, and whereas some studies show a beneficial effect 
of bisphosphonates on fracture risk, others did not. In this Chapter, we also report on 
a case series of 39 patients treated with bisphosphonates within the first year after 
transplantation a median of 185 days after OLT, using as controls patients transplanted 
in the same time period but not receiving bisphosphonates. We observed that BMD 
increased in both treated and untreated patients with no significant difference between 
groups. These results suggest that bisphosphonate treatment not immediately initiated 
after transplantation may be too late to prevent or decrease bone loss characteristic of 
the early post-transplantation period and its associated increased fracture risk.
concluding remarKs and clinical imPlications
Low bone mass and vertebral fractures are highly prevalent in patients with end-stage 
liver failure awaiting liver transplantation, there is a rapid bone loss early after liver 
transplantation and the incidence of new fractures significantly increases within the 
first year after transplantation despite significant recovery of bone mass. Fractures 
represent a significant cause of morbidity and mortality so that it is of high clinical 
relevance to identify factors associated with this skeletal complication of liver 
transplantation. In this Thesis we show that neither clinical parameters such as primary 
liver pathology or severity of liver disease nor BMD measurements or bone turnover 
markers can reliably predict fracture risk before or after liver transplantation. It is clear 
that factors other than bone quantity play a significant role in the increased fracture 
risk and altered bone quality is a prime contender for this role. There are to date no 
reliable means of assessing bone quality, and it is not clear whether currently available 
bone-modifying treatments may positively influence bone quality to decrease or 
prevent future fractures. Taken together, findings from this Thesis are clinically very 
relevant, as they suggest that awareness should be raised amongst physicians caring 
for patients with liver disease about the inevitable skeletal complications associated 
with failure of the metabolic and excretory function of the liver, and all attempts made 
at early correction of all reversible aspects of this failure to try and avoid the increased 





Levertransplantatie wordt vaak gecompliceerd door aandoeningen van het skelet 
zoals botontkalking (osteoporose) en botbreuken. Zoals wordt beschreven in 
Hoofdstuk 1 speelt de lever een cruciale rol in het nauwkeurig afgestemde proces 
van de botombouw. De lever is onder andere belangrijk voor de opname van 
vet-oplosbare vitamines zoals A, E, D en K, waarvan de laatste twee belangrijk 
zijn voor het botmetabolisme, en voor het omzetten van hormonen zoals IGF-1 
en de geslachtshormonen, die ook belangrijk zijn voor normale botombouw. Bij 
leverziekten beïnvloeden naast de verminderde leverfunctie ook andere factoren het 
botmetabolisme. Zo kan een chronische ontsteking door de onderliggende ziekte, 
zoals virale hepatitis of de inflammatoire darmziekte (Morbus Crohn) bij primaire 
scleroserende cholangitis, het botmetabolisme negatief beïnvloeden, en hebben 
langdurig overmatig alcoholgebruik en stapeling van giftige stoffen zoals ijzer bij 
hereditaire hemochromatose of galzouten bij cholestatische leverziekten een direct 
nadelig effect op de botcellen. Er wordt dan ook bij patiënten die in afwachting zijn 
van een levertransplantatie een verminderde botmassa en een sterk verhoogd risico op 
botbreuken beschreven.
Ondanks het herstel van de leverfunctie treedt na levertransplantatie aanvankelijk 
verder botverlies op en maakt ongeveer een derde van de getransplanteerde 
patiënten een nieuwe botbreuk door. Een belangrijke oorzaak van dit botverlies is de 
afweerremmende medicatie die nodig is om afstotingsreacties na transplantatie te 
voorkomen en te behandelen. Patiënten worden na levertransplantatie behandeld 
met onder andere hoge doseringen corticosteroiden, die de botafbraak versnellen en 
de botaanmaak onderdrukken, en met calcineurineremmers, die naast hun directe 
negatieve effecten op de botombouw ook geassocieerd zijn met een verminderde 
nierfunctie wat weer een ongunstige invloed heeft op het bot door een verstoorde 
vitamine D omzetting.
In Hoofdstuk 2 hebben we de botmassa en het aantal doorgemaakte botbreuken 
onderzocht bij patiënten die in afwachting waren van een levertransplantatie. Bij het 
grootste deel van de patiënten was de botmassa al laag ten tijde van de screening voor 
transplantatie, waarbij bij de meesten een voorloper van botontkalking (osteopenie) 
werd gezien. Bovendien had ruim de helft van de patiënten op dat moment al één 
of meerdere milde wervelbreuken doorgemaakt. Er was geen relatie tussen de 
botminerale dichtheid (BMD) en de botbreuken; een groot deel van de patiënten met 
een doorgemaakte wervelbreuk had een normale of slechts minimaal verlaagde BMD, 
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hetgeen suggereert dat bij patiënten met een eindstadium leverziekte een verminderde 
kwaliteit van het bot een belangrijkere rol speelt dan de botmassa bij het ontstaan van 
botbreuken.
In Hoofdstuk 3 hebben we bestudeerd wat er gebeurde met de botmassa en 
het aantal botbreuken na levertransplantatie. Tijdens de eerste zes maanden na 
levertransplantatie trad een forse daling van de botmassa op en binnen het eerste jaar 
na transplantatie maakte twee derde van de patiënten een nieuwe wervelbreuk door. 
Na de eerste zes maanden na transplantatie stabiliseerde de botmassa van de heupen 
en trad herstel op van de botmassa van de wervelkolom, waarbij de BMD twee jaar na 
transplantatie terug was op het niveau ten tijde van de screening voor transplantatie. 
Het bleek moeilijk om te voorspellen welke patiënten na transplantatie een botbreuk 
zouden doormaken; er was geen relatie tussen de BMD op het tijdstip van de screening 
voor transplantatie en het ontstaan van wervelbreuken na levertransplantatie en 
van alle potentiële risicofactoren waren alleen mannelijk geslacht en hogere leeftijd 
geassocieerd met verhoogd risico op botbreuken. Alle andere factoren, zoals vitamine D 
deficiëntie en de mate van leverfalen, waren niet voorspellend.
Het is dus moeilijk gebleken om factoren aan te wijzen bij 
levertransplantatiepatiënten die geassocieerd zijn met een verhoogd risico op 
botbreuken. Er was nauwelijks samenhang tussen klinische parameters zoals de 
aard van de leverziekte, BMD en risico op botbreuken. Er zijn biochemische markers 
van botaanmaak en botafbraak beschikbaar die men kan meten in bloed en urine en 
waarvan bekend is dat ze kunnen worden gebruikt om botverlies en botbreuken te 
voorspellen bij postmenopauzale vrouwen. Een aantal van deze markers zijn afkomstig 
van de aanmaak en afbraak van het type bindweefselmoleculen dat veel in bot 
voorkomt, namelijk type 1 collageen. Echter, de voorspellende waarde van deze markers 
voor botverlies en botbreuken bij transplantatiepatiënten is nog onduidelijk en er is veel 
discussie over de waarde van deze markers bij het behandelen van skeletcomplicaties 
na orgaantransplantaties. Bij chronische leverziekten, zowel voor als na transplantatie, 
zijn er namelijk veel potentiële valkuilen bij het meten en interpreteren van deze 
markers. Zo is er aan de ene kant een verhoogde aanmaak van bindweefsel in de 
lever, waaronder van het type 1 collageen, maar is ook er verhoogde afbraak van dit 
bindweefsel door factoren gerelateerd aan orgaantransplantaties, zoals het gebruik van 
de afweerremmende medicatie, met name corticosteroiden en calcineurineremmers. In 
Hoofdstuk 4 wordt beschreven dat ten tijde van screening voor levertransplantatie de 
botmarkers N-terminaal pro-peptide  en C-terminaal telopeptide van type 1 collageen 
(P1NP en CTX) bij veel patiënten verhoogd waren en osteocalcine verlaagd, maar dat 
de hoogte van deze markers alsook het bot-specifiek alkalisch fosfatase (BALP) niet 
gerelateerd waren aan de verlaagde botmassa of doorgemaakte wervelbreuk. Het 
bleek ook moeilijk om met de botmarkers botverlies en botbreuken ná transplantatie te 
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voorspellen. Alleen hoge CTX spiegels ten tijde van screening voor transplantatie en een 
stijging van BALP na transplantatie waren geassocieerd met botverlies en botbreuken in 
het eerste jaar na levertransplantatie. Vanwege de vele valkuilen bij de interpretatie van 
deze van collageen afkomstige markers van botombouw moet men dus ook voorzichtig 
zijn bij het gebruik van deze markers bij de besluitvorming rondom de behandeling van 
skeletcomplicaties bij patiënten met leverziekten en na levertransplantatie.
In de voorgaande hoofdstukken lieten we zien dat skeletcomplicaties veel voorkomen 
bij levertransplantatiepatiënten. Het is echter nog niet duidelijk hoe deze patiënten 
zouden moeten worden behandeld om botverlies en botbreuken te voorkomen. In 
Hoofdstuk 5 wordt een overzicht gegeven van de resultaten van alle beschikbare 
wetenschappelijke onderzoeken naar de behandeling van levertransplantatiepatiënten 
met bisfosfonaten (geneesmiddelen die de botafbraak remmen en het bot versterken). 
De resultaten laten zien dat behandeling met deze middelen, als die kort na 
levertransplantatie is gestart, over het algemeen botverlies voorkomt en de botmassa 
doet verbeteren. Gegevens over effecten van bisfosfonaatbehandeling op botbreuken 
zijn inconsistent; sommige studies laten een gunstig effect zien van bisfosfonaten op 
het risico op botbreuken, en andere weer niet. Bovendien is nog onduidelijk of deze 
behandeling ook op de lange termijn na levertransplantatie de botmassa verbetert en 
de kans op botbreuken verlaagt.
Verder beschrijven we in dit Hoofdstuk een serie van 39 levertransplantatiepatiënten 
die werden behandeld met bisfosfonaten en waarbij deze behandeling werd gestart 
tijdens het eerste jaar na levertransplantatie (meestal een half jaar of later na 
transplantatie). De behandelde patiënten werden vergeleken met patiënten die 
in dezelfde periode zijn getransplanteerd, maar die niet werden behandeld met 
bisfosfonaten. We zagen dat de botmassa verbeterde bij zowel de behandelde als de 
onbehandelde patiënten en dat er geen verschil was tussen de groepen. Deze resultaten 
suggereren dat als de behandeling met bisfosfonaten niet direct na transplantatie 
wordt gestart, deze te laat is om het botverlies, wat vooral optreedt tijdens de eerste 
periode na transplantatie, te kunnen voorkomen en om het daarbij horende verhoogde 
risico op botbreuken te verlagen.
concluderende opmerkingen en implicaties voor de kliniek
Het merendeel van de patiënten met eindstadium leverziekte in afwachting van een 
levertransplantatie heeft een lage botmassa en heeft al één of meerdere botbreuken 
doorgemaakt. In de eerste periode na transplantatie treedt fors botverlies op, maar 
ondanks het uiteindelijk herstel van de botmassa daarna maakt een groot deel 
van de patiënten in het eerste jaar na levertransplantatie een botbreuk door. Deze 
botbreuken zorgen voor een grote ziektelast en verhogen de kans op overlijden. Het 
is dus ook van groot belang om factoren te identificeren die geassocieerd zijn met de 
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skeletcomplicaties van een levertransplantatie. In dit proefschrift laten wij zien dat noch 
klinische parameters, zoals de onderliggende leverziekte en de ernst van leverfalen, 
noch de BMD en biochemische markers van botombouw het risico op botbreuken 
voor en na levertransplantatie betrouwbaar kunnen voorspellen. Het is duidelijk dat 
andere factoren dan de botmassa een belangrijke rol spelen bij het verhoogde risico 
op breuken, waaronder een veranderde kwaliteit van het bot. Er zijn tot op heden geen 
betrouwbare methoden om de kwaliteit van het bot te meten en het is niet duidelijk 
of de beschikbare bot-modulerende medicamenten de botkwaliteit dusdanig kunnen 
beïnvloeden dat botbreuken worden voorkomen en het risico op breuken wordt 
verkleind.
Concluderend, de bevindingen van dit proefschrift zijn uitermate relevant omdat 
zij laten zien dat er meer aandacht zou moeten zijn van de behandelend artsen 
van patiënten met leverziekten voor de onvermijdelijke skeletcomplicaties van het 
langdurig falen van de lever. Een correctie van alle omkeerbare aspecten van dit falen 
zou in een zo vroeg mogelijk stadium al moeten worden nagestreefd, zodat een afname 
van de kwaliteit van het bot wordt voorkomen en zodat het daarmee geassocieerde 




25(OHD)D  25-hydyroxy vitamin D
ALP  alkaline phosphatase
APC  adenomatous polyposis
AIH  auto-immuun hepatitis
BALP  bone-alkaline phosphatase
BMD  bone mineral density
BMI body mass index
BMP   bone morphogenic protein
BMU’s  bone remodeling units
BTMs  bone turnover markers
CI confidence interval
CV  coefficient of variation
CTX  C-terminal telopeptide, beta crosslaps
DAAM1  dishevelled associated activator of morphogenesis 1
DAG   dystroglycan
DBP  vitamin D binding protein
DKK1  Dickkopf-1
DVL  dishevelled
DXA  dual-energy X-ray absorptiometry
ECLIA Electro-Chemo-Luminescence Immunoassay
ELISA enzyme-linked immunosorbent assay
FGF-23  fibroblast growth factor-23
FN  femoral neck
FZD  Frizzled 
GEE  generalized estimation equations
HBV hepatitis B virus
HCV hepatitis C virus
IFCC International Federation of Clinical Chemistry and Laboratory Medicine
IGF-1  insulin-like growth factor-1
IGFBP  insulin-like growth factor binding protein 
IL  interleukin
IOF International Osteoporosis Foundation 
IP3  inositol 1,4,5-trisphosphate, type 3
IRMA immunoradiometric assay
JNK  Jun kinase
LPR-5  lipoprotein receptor-related protein-5
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LUMC Leids Universitair Medisch Centrum / Leiden University Medical Centre
M-CSF  macrophage colony-stimulating factor
MELD  Model for End-stage Liver Disease
MMF  mycophenolate mofetil
NFATc1  nuclear factor of activated T-cells, cytoplasmic, calcineurin dependent 1
NHANES National Health and Nutrition Examination Survey 
NTX N-terminal telopeptide




P1NP  procollagen type 1 N-terminal propeptide
PBC  primary biliary cirrhosis
PDGF  platelet derived growth factor
PGE-2  prostaglandin E-2
PLC  phospholipase C
PPAR- γ  peroxisome proliferator activated receptor-γ
PSC  primary sclerosing cholangitis
PTH  parathyroid hormone
PTHrP  parathyroid hormone related peptide
RANK  receptor activator of nuclear factor kappa B
RANKL  receptor activator of nuclear factor kappa B- ligand
RCT  randomized controlled trial
ROCK  RHO-associated kinase
ROR  receptor-tyrosine-kinase-like orphan receptor
RUNX2  Runt-related transcription factor 2
SD  standard deviation
SFRP  secreted frizzled-related proteins 
SHBG  sex hormone binding globulin
TCF/LEF   T cell factor/lymphoid enhancer factor
TGF-beta  transforming growth factor beta
TNF   tumor necrosis factor
TPO  thrombopoietin
Ub  polyubiquitination
VDR  vitamin D receptor
VF  vertebral fractures
WHO World Health Organisation




Dit proefschrift vindt haar oorsprong in een uitstapje naar de faculteit 
Geesteswetenschappen, waar ik colleges van hoogleraren Piet Emmer en Leonard 
Blussé heb bijgewoond over de geschiedenis van de Nederlandse en Europese 
expansie overzee. De vrijstelling die mijn opgedane kennis over uitgewisselde 
ziekten tussen Europa en de Nieuwe Wereld opleverde, gaf mij de ruimte voor een 
extra wetenschapsstage in mijn derde studiejaar bij Neveen Hamdy op de afdeling 
Endocrinologie en Stofwisselingsziekten van het Leids Universitair Medisch Centrum 
(LUMC). Vanaf die tijd heeft Neveen mij als co-promotor begeleid en mij veel geleerd 
over alle aspecten van het opzetten en uitvoeren van wetenschappelijk onderzoek. 
Daarnaast is zij als interniste met een schat aan kennis en wijze woorden voor mij 
een mentor geweest tijdens de roerige jaren van mijn co -schappen en opleiding tot 
internist. 
Toen ik besloot om mijn proefschrift te schrijven over levertransplantatiepatiënten 
werd Bart van Hoek van de afdeling Maag-Darm-Leverziekten mijn promotor. Hij heeft 
een belangrijke bijdrage geleverd bij het opzetten van het onderzoek, het verkrijgen 
van de onderzoeksgegevens en bij het begeleiden van mijn promotietraject. Olaf 
Dekkers heeft mij geholpen bij de onderzoeksopzet, de structuur van de artikelenen 
de analyses, die dankzij hem van een kwaliteit zijn waar ik bijzonder trots op ben.. 
Herman Kroon van de afdeling radiologie heeft een belangrijke bijdrage geleverd 
door de vele wervelkolomfoto’s te beoordelen.  Vanuit het verre Universitair Medisch 
Centrum Groningen heeft klinisch chemicus Eveline van der Veer met haar kennis over 
botmarkers bijgedragen door deze te bepalen uit de ingevroren monsters en mee te 
denken bij de interpretatie van de data. 
Een aantal hoogleraren heeft vanaf de zijlijn veel betekend voor mijn promotietraject 
en zonder hun hulp was dit proefschrift niet tot stand gekomen: Hans Romijn, Jan Smit, 
Jan Vandenbroucke, Jaap van Dissel, Alberto Pereira Arias en Ton Rabelink. Zij hebben 
vanuit hun rol als opleiders en afdelingshoofden meegedacht, mij gemotiveerd en 
geïntroduceerd bij de sleutelfiguren voor mijn promotietraject. Hiervoor was vaak een 
kort gesprek op de gang van een stafcentrum of tijdens de lunch op de piste in Kaprun al 
genoeg om mij vooruit te helpen.    
Promotieonderzoek combineren met de opleiding tot medisch specialist is niet 
mogelijk zonder een werkomgeving die dat ondersteunt. De stafleden van de afdeling 
Endocrinologie van het LUMC en mijn collega-fellows hebben mij in die periode 
bijgestaan met hun adviezen en geduld en door waar nodig mijn klinische taken waar 
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te nemen: Hanno Pijl, Noortje van der Kleij, Nienke Biermasz, Natasha Appelman, Eelco 
de Koning, Nienke Niemeijer, Esther Donga, Marielle Schroijen en Mathilde Bruinsslot-
Steenks. De promovendi van de afdeling hebben mij geholpen met aanwijzingen over 
praktische zaken rondom het promoveren en met hun gezelschap tijdens congressen, 
cursussen en op de werkvloer in de kantoortuin: Kim Claessen, Frank Malgo, Sjoerd 
Joustra en Cornelie Andela. Logistieke ondersteuning heb ik gehad van het secretariaat 
van het stafcentrum Endocrinologie (met name Marjolein Iken en Marianne Sjardin) en 
van Eveline de Lange, aanvankelijk als secretaresse van Neveen en later als lid van het 
opleidingsteam interne geneeskunde.  
Mijn vriendinnen hebben mij in mijn opleidings- en onderzoeksjaren gesteund 
met hun interesse en adviezen en met de afleiding die hun gezelschap mij bood. Met 
name wil ik Karen Heemstra en Verzana Mokiem bedanken voor hun inspanningen als 
paranimfen rondom de verdediging van mijn proefschrift. Noortje Pannebakker heeft 
mij vaak gemotiveerd om door te zetten en waardevol advies gegeven over allerlei 
aspecten rondom mijn promotietraject. 
De steun vanuit mijn familie is altijd erg belangrijk geweest. Ik wil dan ook graag mijn 
oma Gertrud Krol en haar zus, mijn oud-tante Anja Mockenhaupt, bedanken voor hun 
niet-aflatende interesse in de voortgang van mijn promotie en hun aanmoediging. 
Tot slot wil ik mijn ouders Peter en Inge Krol bedanken. De vrijheid die zij mij hebben 
gegeven om te worden wie ik wilde zijn, met als enige voorwaarde het beste uit mezelf 
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